Abstract: The FBXW7 (f-box with 7 tandem WD40) protein encoded by the gene FBXW7 is one of the crucial components of ubiquitin ligase called Skp1-Cullin1-F-box (SCF) complex that aids in the degradation of many oncoproteins via the ubiquitin-proteasome system (UPS) thus regulating cellular growth. FBXW7 is considered as a potent tumor suppressor as most of its target substrates can function as potential growth promoters, including c-Myc, Notch, cyclin E, c-JUN, and KLF5. Its regulators include p53, C/EBP-δ, Numb, microRNAs, Pin 1, Hes-5, BMI1, Ebp2. Mounting evidence has indicated the involvement of aberrant expression of FBXW7 for tumorigenesis. Moreover, numerous studies have also shown its role in cancer cell chemosensitization, thereby demonstrating the importance of FBXW7 in the development of curative cancer therapy. This comprehensive review emphasizes on the targets, functions, regulators and expression of FBXW7 in different cancers and its involvement in sensitizing cancer cells to chemotherapeutic drugs.

Keywords: FBXW7; SCF complex; tumor suppressor; mutations; cancer; chemoresistance; chemosensitization

1. Introduction

Despite the advancement in the management of cancer, it remains the leading cause of mortality, accounting for 14.1 million new cases and 8.2 million deaths in 2012 worldwide [1–5]. It is well proven that tumorigenesis involves perturbation of various essential molecular pathways and
biological processes including ubiquitination. Ubiquitination involves proteosomal degradation via the ubiquitin-proteasome system (UPS) and is the key eukaryotic proteolytic mechanism for more than 80% of proteins involved in cell cycle, cell growth and apoptosis [6]. Thus, dysregulation of the UPS may lead to the development of various diseases including cancer. During ubiquitination, the ubiquitin protein binds with the target protein and necessitates the sequential function of three enzymes namely, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2) and ubiquitin ligase (E3). The ubiquitin ligase (E3) binds to the substrate proteins and subsequently causes their degradation via the 26S proteasomes. Studies showed that modulation of ubiquitin ligase E3 function is one the prime factor for initiation and progression of cancer [7,8].

Among the many types of E3 ubiquitin ligases, the SCF (Skp1-Cullin1-F-box) complex that consists of scaffold protein Cullin1 (Cul1), RING finger protein Rbx1, linker protein S phase kinase-associated protein 1 (Skp1), and F-box protein has been extensively studied [8]. SCF complex/E3 ubiquitin ligase governs the substrate proteins for ubiquitylation and subsequent proteasomal degradation via the UPS (Figure 1). Nearly 80–90% of intracellular proteins are degraded via UPS [9]. The Cul1 domain of SCF functions as the catalytic core, Skp1 domain joins the F-box coupled with WD and LRRs motif and the F-box domain can serve as a substrate receptor of the SCF complex and recruits substrate for ubiquitination [8].

![Figure 1. Mode of function of FBXW7.](image)

In humans, 69 F-box proteins have been identified so far and the F-box motif is usually located in the amino-terminal of the protein and the carboxyl terminal is coupled with other motifs such as WD (tryptophan and aspartic acid) or leucine-rich repeats (LRR). Based on this, F-box is classified as FBXW (F-box coupled with WD repeats), FBXL (F-box coupled with LRRs) and FBXO (F-box with no motifs) [8,12]. The F-box motif of the FBXW and FBXL binds with the Skp-1 subunit while the WD and LRRs motifs recognize large arrays of protein for ubiquitination and undergo proteolysis via the 26S proteasomes [12,13]. Increasing lines of evidence have revealed that aberrant expression of F-box is associated with development, proliferation, angiogenesis, and metastasis of various malignancies [8]. Amongst the F-box family, F-box with 7 tandem WD40 repeats (FBXW7) which are responsible for recognizing and targeting various oncogenic substrates for ubiquitin-mediated degradation has been found to be deregulated in diverse cancers [13,14].

### 2. FBXW7

An F-box with 7 tandem WD40 repeats (FBXW7; also known as Fbw7, Sel-10, hCdc4, hAgo or Archipelago) encoded by the gene FBXW7, is a member of F-box, FBXW sub-family with highly conserved F-box motif of about 40 amino-acid [15,16]. It was first identified in budding yeast in 1973.
as Cdc4 [17]. The human FBXW7 gene is located at chromosome 4q31q.3, which is a region deleted in 30% of cancers [18,19], and consists of 4 untranslated and 13 coding exons [20].

The FBXW7 exist in three isoforms namely FBXW7α, FBXW7β, and FBXW7γ, with distinct cellular localization, i.e., FBXW7α is located in the nucleoplasm, FBXW7β resides in the endoplasmic reticulum, and FBXW7γ is found in the nucleolus [13]. Structurally, these isoforms differ only at their N-terminal region and share conserved domains in the C-terminal region. Each of them consists of three vital domains, namely (i) dimerization domain, (ii) the F-box domain and (iii) 7 tandem WD40 repeats (Figure 2). The F-box domain binds the FBXW7 to the Skp1 component of the SCF complex [13]. The WD40 repeat makes up the propeller and consists of three arginine residues and binds to the phosphorylated substrate through recognition of conserved phosphorylated domain, called Cdc4 phosphodegron (CPD) phosphorylated by glycogen synthase kinase 3 (GSK3) [16,21]. The dimerization domain helps in the binding of FBXW7 to the substrate [15].

![Figure 2. Structure of FBXW7.](image)

Aforementioned, FBXW7 is one of the key components of the SCF complex, and aids in substrate recognition for ubiquitination and subsequent proteasomal degradation by the 26S proteasome [16]. The ubiquitin-conjugating enzyme (Ubc) attaches to the SCF complex and transports ubiquitin (Ub) into substrates bounded on the F-box protein. After multiple ubiquitin molecules bind to the substrate, it gets degraded by the 26S proteasome [12]. Studies have shown that under normal biological conditions, FBXW7 is essential for safeguarding bone marrow erythroid cells maturation by regulating the expression of cyclin E [22]. It also mediates the differentiation and proliferation of stem and progenitor cells and is involved in maintaining normal hematopoiesis [23]. Moreover, FBXW7 helps in the regulation of NSC (neural stem cell) differentiation and studies have indicated that brain-specific ablation of FBXW7 led to the accumulation of Notch1 as well as c-Jun that may result in increased self-renewal capabilities of NSC. FBXW7 may also be responsible for pluripotency of embryonic stem cells (ESCs) by controlling c-Myc protein stability [16].

More importantly, FBXW7 is considered as a strong p53-dependent tumor suppressor governing human cell cycle progression, cell growth, and tumor development by directing certain oncoproteins such as cyclin E, notch, c-Jun, c-Myc, mammalian target of rapamycin (mTOR), for ubiquitin-mediated proteolysis [24–29]. Additionally, numerous studies have indicated that inactivation or downregulation of FBXW7 can result in the deregulation of these oncoproteins and may lead to tumorigenesis in human as well as the development of chemoresistance [6,30].

3. Substrates of FBXW7

As indicated above, FBXW7 is a potent tumor suppressor and that can regulate the expression level of many oncoproteins that partake in cellular pathways by directing them for proteasomal degradation thus preventing tumorigenesis. For instance, it is well evidenced that deregulation of proto-oncogene c-Myc leads to the development of many human cancers. It has been reported that FBXW7α ubiquitylates c-Myc in the nucleoplasm and FBXW7γ ubiquitylates c-Myc in the nucleolus,
thereby facilitating proteasomal degradation and thus inhibiting the c-Myc ability to promote cancer cell growth [11,13]. However, downregulation of FBXW7 can lead to an increased level of both cellular and active chromatin-bound c-Myc, without affecting other FBXW7 targeted genes [31] (Figure 3).

Another oncoprotein, Notch, that has been reported to participate in the development of tumor can also be ubiquitylated by FBXW7 for degradation [32]. However, in a T-cell acute lymphoblastic leukemia (T-ALL) patient, a mutation in FBXW7 caused the production of an elevated amount of Notch protein [33]. Further, deletion of FBXW7 in bone-marrow-derived stromal cells (BMSCs) resulted in the accumulation of Notch which consequently rendered elevation of chemokine (C-C motif) ligand 2 (CCL2), thereby promoting cancer metastasis in vivo [34].

Additionally, it is well-known that transcription factor, nuclear factor kappa B (NF-κB) controls cell survival, tumor invasion, and drug resistance, through the regulation of multiple oncogenic gene products [35–62]. Reports have indicated that NFκB2/p100 can interact with FBXW7 thereby prompting its degradation in a GSK3β phosphorylation-dependent manner [63,64]. Another substrate, heat-shock factor 1 (HSF1), that regulates the heat-shock response and supports malignancy has been reported to be ubiquitylated by FBXW7α via a conserved motif phosphorylated by GSK3β and ERK1. In most cancers, including melanoma, FBXW7α is mutated or downregulated resulting in impaired degradation of HSF1, which increased the accumulation HSF1, thus, enhancing the metastatic potential of human melanoma [65].

Another substrate of FBXW7 is a transcription factor, kruppel-like factor2 (KLF2), has been reported to exert cell growth-inhibitory, pro-apoptotic and anti-angiogenic activities [28,66]. Studies have revealed that FBXW7 may mediate KLF2 degradation via phosphorylation of KLF2 by glycosynthase kinase-3 (GSK3) at the two CPD domain on KLF2 [28]. In line with this finding, it has been demonstrated that knockdown of FBXW7 can upregulate KLF2 in endothelial cells thereby regulating the endothelial cell migration, angiogenesis, and endothelial barrier integrity in vivo [67]. FBXW7 has also been reported to ubiquitylate and degrade oncogenic transcription c-Jun through the phosphorylation of c-Jun by GSK3β [68]. Besides these, FBXW7 can also ubiquitylate several other essential proteins such as Aurora A, cyclin E, mTOR (mechanistic target of rapamycin), SREBP (sterol regulatory element-binding protein), NF1 (Neurofibromatosis type 1), NRF1 (nuclear factor E2-related factor 1), and MED13 (mediator 13) [28,31].

4. Regulation of FBXW7

Accumulating studies have shown that mutations and/or deletions of FBXW7 have been implicated in numerous human tumors, thus, indicating that aberrant regulation of FBXW7 is one of
the prime factors for tumorigenesis. Some of the regulators of FBXW7 include tumor suppressor p53, Pin1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting1), C/EBP-δ (CCAAT/enhancer-binding protein-δ), Hes-5 (Hairy and Enhancer-of-split homologues 5), Numb, and microRNAs (miRNAs) such as miR-27, and miR-223 [28] (Figure 3).

4.1. p53

Studies have found that the initial exon of FBXW7 harbors p53-binding site, making it one of the targets of p53 [69]. Moreover, reports have revealed a significant upregulation of FBXW7 when p53 deficient cells were infected with adenovirus-mediated wild-type p53. It was also reported that the expression level of FBXW7 may directly correlate with that of p53. More importantly, p53-dependent suppression of FBXW7 activated aurora-A, c-Jun, and Notch leading to genetic instability [28]. Studies have also indicated that in gastric cancer patients with the p53 mutation, decreased expression of FBXW7 with distinctively poor prognosis was observed [25]. Further, it has been shown that FBXW7 and p53 cooperatively inhibited advanced and chromosomally unstable intestinal cancer. Moreover, FBXW7-mutated colorectal cancer cells showed inhibition of phosphorylation of p53 at serine-15. In neuroendocrine cancer, p53 mutation was found to cause inhibition of FBXW7, resulting in upregulation of growth promoter aurora-A [70]. Thus, these studies collectively support p53 as one of the key regulators of FBXW7 and that targeting the p53 signaling pathway would offer a suitable approach to replenish FBXW7 for the development of anti-cancer therapies [28].

4.2. C/EBP-δ

The protein CCAAT/enhancer-binding protein-δ (C/EBPδ), a member of the C/EBP transcription factor family that binds to the DNA through its leucine zipper scissors is another regulator of FBXW7 [71]. It acts as a tumor suppressor and participates in the regulation of cell proliferation and apoptosis but has pro-metastatic properties [71,72]. It has been reported that C/EBPδ enhanced mTOR stability by directly inhibiting the expression of FBXW7, resulting in elevation of hypoxia and inflammatory signaling which in turn promoted tumor cell survival [71,73]. Further studies have revealed that C/EBPδ inhibited the expression of FBXW7, thereby increasing the activities of the FBXW7 substrates such as mTOR and HIF-1α and potentiated metastasis in mammary tumors [74].

4.3. Pin1

Another studied regulators of FBXW7 is prolyl isomerase Pin1 an enzyme that particularly isomerizes Ser/Thr-Pro peptide bonds after phosphorylation to control their conformational changes [28,75]. It has been reported that it may be overexpressed in a majority of human cancers and is associated with poor prognosis [75]. Reports have revealed that Pin1 can negatively regulate the stability and function of FBXW7 by binding to FBXW7 and inducing self-ubiquitination and degradation by altering their dimerization. Thus, overexpression of Pin1 can significantly downregulate FBXW7, thereby consequently augmenting cancer cell progression [28,76].

4.4. Other Regulators

Up-regulation of the Notch signaling effector, Hes-5 is observed in many human cancers and it has been indicated that Hes-5 suppressed the transcription of FBXW7β in colon cancer cells [28,32]. Studies by Jiang et al. depicted that tumor suppressor, Numb4 positively regulate the expression of FBXW7, stimulating its assembly and activation, thus encouraging degradation of its substrate Notch in glioma stem cells [77]. Additionally, it is well demonstrated that aberrant microRNA (miRNA) expression is associated with cancer development. Studies have shown that miR-27 targets FBXW7 and enhanced expression of miR-27 downregulated FBXW7 [78,79]. This downregulation accelerated tumor growth through reduction of FBXW7-mediated ubiquitin-dependent degradation of various oncoproteins including c-Myc, c-Jun, cyclin E1 and Notch 1. Conversely, ablation of miR-27a enhanced FBXW7 expression levels, thereby lowering the levels of its oncogenic substrates such as
cyclin E [78,79]. Further, in leukemia, miR-27 was found to be upregulated leading to depletion of FBXW7 [79]. Similarly, in gastric cancer, miR-223 functions as an oncogene and found to negatively regulate FBXW7 expression that governs the cellular apoptosis, proliferation, and invasion [80]. In line with this, Kumar et al. demonstrated that the Notch-mediated activation of miR-223 suppressed FBXW7 in T-cell acute lymphoblastic leukemia (T-ALL) [81].

Additionally, it has also been found that miR-32 induced cell proliferation, migration and evaded apoptosis in breast cancer in vitro by downregulating FBXW7 [82]. Similarly, in cervical cancer cells upregulation of miR-92a caused downregulation FBXW7, thereby promoting cell proliferation and invasion [83]. Recently, it has also been found that miR-182 increased the proliferation of non-small cell lung cancer cells by suppressing FBXW7 [84]. Further, NF-κB is another possible regulator of FBXW7. It has been indicated that NF-κB p65 which is upregulated in human bladder cancer cells significantly enhanced the cancer cell migration by stabilizing the activity of FBXW7 which in turn ubiquitylated and induced degradation of RHO guanosine diphosphate dissociation inhibitor (RhoGDI)-α protein. Thus, enhancing the tumor suppressive activity of FBXW7 through its regulators can serve as a novel approach in cancer. Nonetheless, further studies on the regulation of FBXW7 expression is warranted for a clearer understanding of the role of FBXW7 in tumorigenesis.

5. Genetic and Epigenetic Alterations of FBXW7 in Cancer

In various human cancers, the purview of the genetic alterations in FBXW7 may foothold its role in tumor suppression. It is in turn responsible for the functional inactivation and degradation of various proto-oncogenes ultimately triggering tumorigenesis [85,86]. Mutation, deletion, and hypermethylation are the main causes for the inactivation of FBXW7 thereby resulting in cancer progression [19,86,87]. Seldom, the FBXW7 is found to be mutated in cancers of the breast, cervix, esophagus, gastric, liver, lung and pancreas [85]. Rather, monoallelic and biallelic FBXW7 gene deletions or promoter hypermethylation are predominantly observed in different cancers for example bladder, breast and cervical cancer. Missense point mutation of FBXW7, however, is the most common type of genetic alteration which impinges the three critical arginine residues of the β-propeller in its phosphate-binding pockets [88].

The different tumors usually express functional wildtype protein by retaining the second wildtype allele of FBXW7. Mono-allelic deletion of FBXW7 displays a milder tumor phenotype compared to the complete gene loss in mouse models [89,90]. Therefore, the FBXW7 mutants are assumed to act as dominant negative alleles, which eventually cause functional inactivation of the wildtype protein [85,88]. The FBXW7 heterozygous mouse displays reduced tumorigenesis compared to knock in mouse harboring a heterozygous FBXW7 mutation in the intestine and the hematopoietic system [88,90,91]. Compared to the FBXW7-null animals, the hematopoietic stem cells in FBXW7\(^{\alpha}{}\) mice can exhibit substantial accumulation of Myc but does not display the hyper-proliferative phenotype characteristic of FBXW7-null animals [90].

Several in vitro, in vivo and clinical studies have shown that FBXW7\(^{\alpha}{}\) is ubiquitously expressed and has broad tissue distribution. However, the expression of FBXW7\(^{\beta}{}\) was found to be differentially expressed in different cell lines and in tissue localization. DNA and histone modifications epigenetically regulate the FBXW7\(^{\beta}{}\) promoter. It is found to be methylated in 51% of breast cancer tumors and 43% in different cancer cell lines [19]. Hypermethylation of the FBXW7 promoter is often linked with mutations in p53, which results in suppressed FBXW7 expression through increased expression of the DNA methyltransferase 1 (DNMT1). Kitade et al. reported that ovarian cancer patients’ display decreased FBXW7 expression with mutated p53 [92]. Histone modifications also play a critical role in the regulation of FBXW7 expression. Enhancer of zeste homolog 2 polycomb repressive complex 2 (EZH2), a histone methyltransferase helps in addition of three methyl groups onto the histone H3 residue, H3K27me3, of FBXW7 which ultimately leads to silencing of FBXW7 gene function [2].

Augmented expression of Notch target gene and Hes5 transcriptional repressor causes the suppression of FBXW7 gene expression and forms a positive feedback loop that strengthens the
FBXW7 loss-of-function phenotype [93]. An activated Notch allele induced T-cell leukemia in mice and shows stabilization of Myc, SREBP1 and several other substrates. Further, the reduction of p53 does not ameliorate the disease onset emphasizing the functional difference between complete gene loss and FBXW7 mutants. However, in other tissues of FBXW7\textsuperscript{Mut/+} mice, most tested FBXW7 substrate level remains unaffected with an exception of TGIF1 and KLF5 implicating that the effect of FBXW7 mutations on substrate turnover is vastly context-dependent [91]. Interestingly, FBXW7 mutation ameliorates Ap\textsuperscript{cmin}-driven intestinal tumorigenesis but the adenomas arising in these mice also possess normal levels of Myc, Notch and Jun. Hence, heterozygous FBXW7 mutations may promote tumorigenesis via regulation of “non-canonical” substrates such as TGIF1 and KLF5 [88]. Keeping in mind the indispensable role of FBXW7 in the maintenance of physiological substrate levels, it is, therefore, essential to understand the mechanisms controlling its activity.

6. Deregulation of FBXW7 in Different Types of Cancer

It is well established that in cancer, the expressions of various genes involved in cell survival, proliferation, invasion, metastasis, chemoresistance and apoptosis are dysregulated [5,94–98]. Interestingly, FBXW7 also plays an important role in the proteasomal degradation of proteins involved in the regulation of cell proliferation and survival such as c-Myc and cyclin E, thereby causing cell cycle exit (G0 phase). Hence, perturbation of the expression of FBXW7 is considered as one of the major causes of cancer development and progression [25]. It was reported that FBXW7 gene mutation in primary human tumors had an overall frequency of 6% point mutation (nonsense and missense mutation) [15,99,100]. In this point mutation, missense mutation leading to the substitution of key arginine residues (Arg\textsuperscript{465} and Arg\textsuperscript{479}) of the WD40 domain takes place, initiating damage of the substrate-binding site of the protein, thereby enhancing tumorigenesis [100]. Besides mutations, FBXW7 pathway may also be perturbed due to the suppression of its expression in tumors or due to the aberration of its regulators [73]. Thus, the normal functioning of FBXW7 may be imperative for the prevention of malignancies [16].

6.1. Brain Cancer

In glioblastoma, FBXW7 is reported to be downregulated. Studies showed that targeted inhibition of overexpressed microRNA-10b (miR-10b) in glioblastoma can lower the activity of miRNA-15/16 thereby, suppressing its direct targets including FBXW7. Further, knock-down of FBXW7 amplified the expression of cell cycle proteins including cyclin A2 and cyclin E2 in basic condition and miR-10b deficient glioma cells, affirming its role as a regulator of cell cycle proteins’ degradation [101]. Moreover, p53 mutation was found to contribute to the development of gliomas by enhancing the expression of c-Myc via downregulating FBXW7, thereby protecting against apoptosis caused by c-Myc [102]. Studies have also shown that in human gliomas, expression of FBXW7\textbeta mRNA is specifically suppressed and plays a key role in the pathogenesis of glioma with increased expression of CCNE1, Myc, and AURKA [103,104]. In medulloblastoma, FBXW7 is either downregulated or mutated, which increased the expression of SOX-9 that further confers cell migration, metastasis, and chemoresistance [105]. In line with this, in vitro overexpression of FBXW7 in U251 and U373 human glioblastoma cells were found to remarkably inhibit the proliferation, invasion and migration [106]. Studies showed that non-coding RNA, human metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) can exert tumor suppressive action by down-regulation of miR-155. Since, FBXW7 mRNA is a direct target of miR-155 in glioma, downregulating miR-155 by MALAT1 resulted in an enhanced expression of FBXW7, thereby suppressing the glioma cell proliferation [107]. It has also been well established that circular RNAs (circRNAs) have crucial roles in carcinogenesis. Recently, studies have indicated that FBXW7 circular RNA, circ-FBXW7 has the potential to repress tumorigenesis in brain cancer and may serve as a prognostic marker for glioma [108] (Table 1).
| Cancer                  | In Vitro/In Vivo/Clinical | Cell Lines | Expression of FBXW7 | Modulation of FBXW7 | Mechanism of Action                  | Ref. |
|------------------------|----------------------------|------------|---------------------|---------------------|--------------------------------------|------|
| **Bone**               | In vitro                   | U2OS, MG-63| ↑FBXW7              | Ectopic overexpression | ↓c-Myc; ↓cyclin E | [27] |
|                        | In vivo Mouse xenografts   | ↑FBXW7     | Ectopic overexpression | ↓c-Myc; ↓cyclin E | [27] |
|                        | In vitro BMSCs              | ↓FBXW7     | -                   | ↑CCL2               | [34] |
|                        | In vitro A172, U87MG, U251MG, U373MG | ↓FBXW7 | -                   | ↑CCNE1; ↑MYC;        | [104] |
| Brain                  | In vivo Mouse xenografts   | ↓FBXW7     | Overexpressed p53 mutants (C132W and R270C) | ↑c-Myc            | [102] |
|                        | In vitro U87, SHG139       | ↑FBXW7     | MALAT1 induced overexpression | ↓Cell viability | [107] |
|                        | In vitro U343MG, Daoy      | ↓FBXW7     | siRNA-mediated silencing | ↑SOX9             | [105] |
|                        | In vitro U251, U373        | ↑FBXW7     | Ectopic overexpression | ↓Aurora B; ↓MCL-1; | [106] |
|                        | In vitro U251, U373        | ↓FBXW7     | Ectopic overexpression | ↓c-Myc            | [108] |
|                        | In vitro DLD1              | ↑FBXW7     | Ectopic overexpression | ↓KLF5 protein   | [109] |
|                        | In vitro T47D              | ↓FBXW7     | siRNA-mediated silencing | ↑c-Myc; ↑cyclin E | [110] |
|                        | In vitro MCF10A, BT549     | ↓FBXW7     | Overexpression of FAM83D | ↑mTOR             | [111] |
|                        | In vivo Wnt9b+/− & Eya1+/− | ↑FBXW7     | -                   | ↑Eya1 ubiquilatin  | [112] |
| Breast                 | In vitro MCF7, T47D, MDA-MB-231 | ↑FBXW7 | siRNA-mediated silencing | ↑MCL-1; ↑PLK-1    | [113] |
|                        | In vitro MCF-7             | ↓FBXW7     | Suppression by 27-HC at transcriptional level | ↑Myc              | [114] |
|                        | In vitro MDA-MB-453, MCF-7 and MCF-10A | ↓FBXW7 | shRNA-mediated silencing | ↑EglN2            | [115] |
|                        | In vitro MCF-7, MDA-MB-231 | ↓FBXW7     | Binding of miR-32 to the 3-UTR of FBXW7 | ↓Apoptosis       | [82] |
|                        | In vitro MDA-MB-23, SKBR   | ↑FBXW7     | Ectopic overexpression | ↓MTDH             | [116] |
| Cholangioc-arcinoma    | In vitro HuCCT1, RBE       | ↓FBXW7     | shRNA-mediated silencing | ↑EMT              | [117] |
|                        | In vivo HuCCT1-shFBXW7 injected mice | ↓FBXW7 | shRNA-mediated silencing | ↑EMT              | [117] |
|                        | In vitro Tissue samples    | ↓FBXW7     | -                   | ↑c-Myc; ↑Ki-67    | [118] |
### Table 1. Cont.

| Cancer        | In Vitro/In Vivo/Clinical | Cell Lines                              | Expression of FBXW7 | Modulation of FBXW7          | Mechanism of Action                          | Ref.  |
|---------------|---------------------------|-----------------------------------------|---------------------|------------------------------|---------------------------------------------|-------|
| Colorectal    | In vitro                  | LoVo, Colo 201                          | ↓FBXW7              | siRNA-mediated silencing     | ↑c-Myc; ↑cyclin E                         | [119] |
|               | In vitro                  | SW620, HT29, HCT116                     | ↓FBXW7              | Knockdown of Rictor          | ↑c-Myc; ↑cyclin E                         | [120] |
|               | In vivo                   | FBXW7flox/flox mice                     | ↓FBXW7              | Conditional deletion         | ↑c-Myc; ↑cyclin E                         | [121] |
|               | In vitro                  | HCT116, DLD-1                           | ↓FBXW7              | Depletion                   | ↑EMT                                        | [99]  |
|               | In vitro                  | HCT116                                  | ↑FBXW7              | Ectopic overexpression      | ↓ENO1                                       | [122] |
|               | In vitro                  | SW480, RKO                              | ↓FBXW7              | Degradation by PLK2         | ↑Cyclin E                                  | [123] |
|               | In vivo                   | Mouse xenografts                        | ↓FBXW7              | Degradation by PLK2         | ↑Cyclin E                                  | [123] |
|               | In vitro                  | HCT116, DLD1, RKO, LoVo                | ↑FBXW7 mutant       | -                            | ↑MCL-1                                     | [124] |
|               | In vitro                  | SW480, HCT116                           | ↑FBXW7              | FAM83D knockdown            | ↓Notch1                                    | [125] |
|               | In vitro                  | HT-29, SW480, SW620, LoVo               | ↓FBXW7              | Binding of miR-223 to the 3-UTR of FBXW7 | ↑EMT                                        | [126] |
| Esophageal    | In vitro                  | TE8, Eca109, EC9706, KYSE30             | ↓FBXW7              | Binding of miR-27a-3p to the 3-UTR of FBXW7 | ↓G1/S arrest                               | [127] |
| Gastric       | In vitro                  | ACP02, ACP03                            | ↓FBXW7              | Deletion of one copy of FBXW7 | ↑c-Myc                                     | [128] |
|               | In vitro                  | -                                       | ↓FBXW7              | Binding of miR-25 to the 3-UTR of FBXW7 | -                                           | [129] |
|               | In vitro                  | AZ-521, MGC-803, BGC-823, SGC-7901      | ↑FBXW7              | Ectopic overexpression      | ↓RhoA                                      | [130] |
|               | In vivo                   | Mouse xenografts                        | ↑FBXW7              | Ectopic overexpression      | ↓RhoA                                      | [130] |
|               | In vivo                   | FBXW7 knockout mice                     | ↓FBXW7              | Haploinsufficiency          | ↑c-Myc                                     | [131] |
|               | In vitro                  | Tissue samples                          | ↓FBXW7              | -                           | ↓Survival; ↓response                       | [132] |
| Leukemia      | In vitro                  | DU528, CEM, Jurkat                      | ↑FBXW7 mutant       | Misense mutations of arginine (R465 & R505) | ↑MYC; ↑DELTEX1                           | [133] |
|               | In vitro                  | Tissue samples                          | ↑FBXW7 mutant       | Arginine substitutions at R479, R465, R505, and R689 | ↑NOTCH1; favorable outcome               | [134] |
|               | In vitro                  | FBXW7−/− − DLD1                         | ↑FBXW7              | Ectopic overexpression      | ↓MCL-1                                     | [135] |
|               | In vitro                  | Jurkat, CCRF-CEM                        | ↑FBXW7              | Oridonin- mediated upregulation | ↑c-Myc                                     | [136] |
| Cancer | In Vitro/In Vivo/Clinical | Cell Lines | Expression of FBXW7 | Modulation of FBXW7 | Mechanism of Action | Ref. |
|--------|--------------------------|------------|-------------------|------------------|-------------------|-----|
| Leukemia | In vivo | FBXW7 knock-in mice | ↑FBXW7 mutants | Missense mutation | ↑c-Myc stability | [90] |
| Leukemia | In vitro | Molt4, K562 | ↓FBXW7 | shRNA-mediated silencing | ↑GRα | [137] |
| Leukemia | In vivo | T-ALL xenografts | ↑FBXW7 mutant | R479Q mutation | ↑GR stability | [137] |
| Leukemia | In vitro | Jurkat cells | ↑FBXW7 | Knockdown of TAL1 | ↓Myc; ↓Notch1; ↓Cyclin E | [138] |
| Leukemia | In vitro | MT1 | ↑FBXW7 mutant | Mutation at arginine residues R479Q, R505C, and R465H | ↑Notch 1 | [139] |
| Leukemia | In vitro | SU-DHL-2, OCI-LY-3. | ↑FBXW7 | Ectopic overexpression | ↓STAT3 | [140] |
| Leukemia | Clinical | 50 patients | ↑FBXW7 mutant | - | Better clinical outcome | [141] |
| Liver | In vitro | SMMC-7721, HepG2, Hep3B, HuH7 | ↑FBXW7 | Adenoviral delivery of p53 | ↓c-Myc; ↓cyclin E | [142] |
| Liver | In vitro | HepG2, Hep3B | ↑FBXW7 | Flag-FBXW7 overexpression | ↓YAP | [143] |
| Liver | In vivo | Mouse xenografts | ↑FBXW7 | Flag-FBXW7 overexpression | ↓YAP | [143] |
| Liver | In vitro | SMMC7721, HepG2 | ↑FBXW7 | STAT1 overexpression | ↓Cyclin A, D1, E; ↓CDK2; ↓Hes-1; ↓NF-κB p65 | [144] |
| Lung | In vitro | A549, HCT116 | ↓FBXW7 | siRNA-mediated silencing | ↑MCL-1 | [145] |
| Lung | In vitro | H2009, H1975 | ↓FBXW7 | siRNA-mediated silencing | ↑MCL-1 | [146] |
| Lung | In vitro | H1299, H460 | ↑FBXW7 | - | ↓ZNF322A | [147] |
| Lung | In vitro | Mouse xenografts | ↑FBXW7 | - | ↓ZNF322A | [147] |
| Lung | In vitro | A549, H460, H1299 | ↓FBXW7 | Binding of miR-367 to the 3-UTR of FBXW7 | ↑Wnt signaling | [148] |
| Lung | In vitro | PC-9, HCC827, H3122, H3255, H1975, H1299 | ↓FBXW7 | shRNA-mediated silencing | ↑MCL-1 | [149] |
| Lung | In vitro | A549, H322, H460, GLC-82, SPC-A1 | ↓FBXW7 | MiR-544a overexpression / TINCR knockdown | ↑Proliferation; ↑invasion | [150] |
| Lung | In vitro | PC9, H1299 | ↓FBXW7 | shRNA-mediated silencing | ↑EMT | [151] |
| Lung | In vivo | FBXW7+/− mice | ↓FBXW7 | shRNA-mediated silencing | ↑Tumorigenesis | [151] |
Table 1. Cont.

| Cancer       | In Vitro/In Vivo/Clinical | Cell Lines                        | Expression of FBXW7 | Modulation of FBXW7                  | Mechanism of Action           | Ref. |
|--------------|----------------------------|-----------------------------------|---------------------|-------------------------------------|-------------------------------|------|
| Oral         | In vitro                  | UM1, UM2, Cal27, SCC1, SCC15, SCC25 | ↓FBXW7              | Binding of miR-24 to the 3-UTR of FBXW7 | ↑Tumorigenesis               | [152]|
|              | In vitro                  | Tissue samples                    | ↓FBXW7              | -                                   | Poor prognosis                | [153]|
| Pancreas     | In vitro                  | BxPC-3, Colo-357                  | ↑FBXW7              | Nuclear retention by KPT-185         | ↓Notch1; ↓c-Myc; ↓VEGF       | [154]|
|              | In vivo                   | Colo-357 xenografts               | ↑FBXW7              | Nuclear retention by KPT-185         | ↓Notch1                      | [154]|
| Renal        | In vitro                  | MIAPaCa2, BxPC3, PANC1            | ↓FBXW7              | shRNA-mediated silencing            | ↑β-catenin                   | [155]|
|              | In vitro                  | SUIT-2                            | ↑FBXW7              | siRNA-mediated silencing             | ↑MCL-1                       | [156]|
|              | In vitro                  | PANC-1, Mia PaCa-2                 | ↑FBXW7              | Ectopic overexpression              | ↑ENT1                        | [157]|
| Skin         | In vitro                  | MMRU, RPEP                        | ↓FBXW7              | siRNA-mediated silencing             | ↑MAPK/ERK                    | [15] |
|              | In vitro                  | FBXW7+/− mice                      | ↓FBXW7              | -                                   | ↑c-Myc                       | [160]|
|              | In vivo                   | WC00125, WM39, WM3702, WM3862      | ↓FBXW7              | Nonsynonymous mutations; shRNA-mediated silencing | ↑Notch                      | [161]|
|              | In vivo                   | Lysm− FBXW7+/−, Lysm+ FBXW7+/−     | ↓FBXW7              | Myeloid cell-specific deletion       | ↓MAM                         | [162]|
|              | In vitro                  | S01mel, SKMEL28, SKMEL24, WM3862, WM39 | ↓FBXW7              | shRNA-mediated silencing             | ↓Nuclear HSF1                | [65] |
|              | In vitro                  | MM415, MM485, HT144, A2058, SH4    | ↓FBXW7              | siRNA-mediated silencing             | ↑MITF/PGC-1 signaling        | [163]|

27-HC: 27-hydroxycholesterol; AURKA: Aurora kinase A; BMSCs: bone marrow-derived stromal cells; CCL2: chemokine (C-C motif) ligand 2; CCNE1: Cyclin-E; CDK2: Cyclin-dependent kinase 2; EglN2: Egl-9 Family Hypoxia Inducible Factor 2; EMT: Epithelial-mesenchymal transition; ENT1: Equilibrative nucleoside transporter 1; ERK: Extracellular signal-regulated kinases; Eya: Eyes absent homolog 1; FAM83D: Family with sequence similarity 83, member D; GRα: Glucocorticoid receptor α; HES1: Hairy and enhancer of split-1; HSF1: Heat-shock factor 1; KLF5: Krueppel-like factor 5; MALAT1: metastasis associated lung adenocarcinoma transcript 1; MAM: metastasis-associated macrophage; MAPK: Mitogen-activated protein kinase; MCL-1: Myeloid cell leukemia 1; MITF: Microphthalmia-associated transcription factor; MMP-2: Matrix metalloproteinase-2; MTDH: Metatherin; PGC-1: Peroxisome proliferator-activated receptor gamma coactivator 1-alpha; PKL: Polo-like kinase; Rictor: Rapamycin-insensitive companion of mTOR; STAT3: Signal transducer and activator of transcription 3; TINCR: Terminal differentiation-induced IncRNA; VEGF: Vascular endothelial growth factor; YAP: Yes-associated protein; ZNF322A: Zinc-finger 322A.
6.2. Breast Cancer

In breast cancer, the level of FBXW7 mRNA is comparatively lower than in normal tissues and is associated with poorer prognosis [110,164]. Consistent with this, in vitro silencing of FBXW7 substantially upregulated c-Myc and cyclin E thus, accelerating breast cell proliferation as well as G1-S transition [110]. Additionally, one of the profuse cholesterol metabolites, 27-hydroxycholesterol was found to increase the stability of c-Myc in MCF-7 breast cancer cell via repression of FBXW7 [114]. Further, studies have reported that FBXW7 inhibited breast cell proliferation and tumorigenesis in part by targeting KLF5 for degradation via the ubiquitin-proteasomal pathway [109]. Aforementioned, FBXW7 targets cyclin E for proteolysis. In breast cancer cells, mutated FBXW7 caused significant upregulation of cyclin E, thereby augmenting breast cancer cell proliferation in vitro [165]. Depletion of FBXW7 in triple negative breast cancer (TNBC) was found to upregulate one of the key sensor Egl-9 Family Hypoxia-Inducible Factor 2 (EGLN2), thereby contributing to TNBC development.

Another negative regulator of FBXW7, miR-32 was found to be upregulated in breast cancer cells, and directly binds to the 3′-UTR region of FBXW7 and hence reducing FBXW7 expression which resulted in increased breast cancer cell proliferation, migration and inhibited apoptosis [82]. Studies have affirmed that an oncogene FAM83D (family with sequence similarity 83, member D) present on chromosome 20q has a significant role in breast cancer development by downregulating FBXW7 resulting in amplification of its oncogenic substrates such as mTOR [111].

Aforementioned, the C/EBPδ is one of the negative regulators of FBXW7 and is reported to be induced by hypoxia in breast cancer in vitro and in vivo. This induced C/EBPδ can suppress FBXW7 in breast cancer, consequently increasing oncogenic mTOR/AKT/S6K1 signaling [166–175] as well hypoxia-inducible factor-1α (HIF-1α) required for hypoxia adaptation, thereby promoting tumor metastasis [74]. In vitro forced overexpression of FBXW7 repressed breast cancer cell proliferation and promoted apoptosis by targeting the oncoprotein, metadherin (MTDH) for proteolysis [116] (Table 1).

6.3. Colorectal Cancer (CRC)

Colorectal tumor mutation profiling showed a missense mutation of FBXW7 in chromosome number 4 with a change in the amino acid sequence R425C [176]. A missense mutation was correlated with poor overall survival in colorectal cancer (CRC) patients [177]. The FBXW7 mRNA level was found to be considerably lesser in colorectal tumor tissues compared to the corresponding normal tissues. Additionally, reports suggested that CRC patients with low expression of FBXW7 showed a poor prognosis. In vitro studies showed that suppression of FBXW7 increased colorectal cancer cell proliferation by upregulating c-Myc and cyclin E [119]. Furthermore, it has been reported that rapamycin-insensitive companion of mTOR (Rictor), forms a complex with FBXW7 and promote degradation of c-Myc and cyclin E in CRC cells [120]. In vitro and in vivo studies showed aberrant phosphorylation of p53 at serine 15 in human FBXW7-deficient CRC cells. Further, loss of function of FBXW7 accounts for the development of resistance to chemotherapeutic drug oxaliplatin in HCT116 colorectal cancer cells due to a reduced level of phospho-p53(Ser15) [178]. Another study showed that the depletion of FBXW7 in HCT-116 enhanced the expression of the oncogenic protein enolase 1 (ENO1) in CRC in vitro [122]. It has also been reported that downregulation of FBXW7 promoted epithelial-mesenchymal transition (EMT) and metastasis in CRC cells. However, treatment of colorectal cancer cells with mTOR inhibitor, rapamycin effectively reversed the FBXW7-deficient driven EMT and metastatic characteristics of CRC cells [99].

Additionally, the heat shock protein 90 (Hsp90) was found to exert its anti-cancer effects in CRC cells in vitro via FBXW7-dependent degradation of MCL-1 [124]. Studies have also evinced that knockdown of the family with sequence similarity 83, member D (FAM83D)-promoted apoptosis in CRC in vitro by causing upregulation of FBXW7 which consequently degraded Notch1 [125]. Reports have indicated that upregulation of miR-182 and miR-503 transformed colon adenoma to adenocarcinoma by jointly reducing the expression of FBXW7. Conversely, inhibiting the expression of both miR-182 and miR-503 caused up-regulation of FBXW7 in colon cancer AAC1 cells and considerably
reduced the tumor size in xenograft models [179]. Recently, miR-92b was found to potentiate CRC cell proliferation, invasion, and migration by suppressing FBXW7 in vitro and in vivo [180]. Polo-like kinase 2 (Plk2) was found to instigate tumor growth and evade apoptosis in CRC cells in vitro and in vivo by degrading FBXW7 which rendered subsequent stabilization of cyclin E [123] (Table 1).

6.4. Esophageal Cancer

In esophageal squamous cell carcinoma (ESCC), loss of FBXW7 expression has been indicated due to genetic alteration. Studies showed that cases showing loss of FBXW7 copy number exhibited decreased expression of FBXW7 with a poorer prognosis when compared to cases without loss of copy number [181,182]. As mentioned, FBXW7 is negatively regulated by miR-223 and miR-223 expression was found to be high in ESCC patients which are associated with poor prognosis through the suppression of FBXW7 [28,183]. Additionally, mounting evidence has suggested the role of dysregulated miR-27a-3p in tumorigenesis of various types of cancers. Studies have found that miR-27a-3p is upregulated in ESCC cell lines compared to the corresponding normal cell line and enhanced esophageal cancer cell proliferation by markedly suppressing FBXW7 [127] (Table 1).

6.5. Gastric Cancer (GC)

In gastric cancer (GC) mutation of FBXW7 is observed in both initial and advanced stages. Lee et al. reported six hCDC4/FBXW7 somatic mutations in gastric cancer case studied, out of which four were missense mutations, one was frameshift deletion and one comprised of nonsense mutation [184]. Low expression of FBXW7 was observed in primary gastric cancer and contributed to the poor survival and minimal response to adjuvant therapy [132]. Studies revealed that loss of CDC4/FBXW7 promoted amplification of c-Myc in both early-onset of gastric cancers (EOGC) and conventional gastric carcinogenesis [185]. Additionally, Calcagno et al. revealed that downregulation of FBXW7 and subsequent amplification of c-Myc contributed to the aggressiveness of this disease [128] (Table 1).

Recently, it has been shown that FBXW7 haploinsufficiency accelerated gastric carcinogenesis in N-methyl-N-nitrosourea (MNU)-induced GC mice model by triggering DNA damage and upregulation of c-Myc [131]. It has also been indicated that miR-25 was overexpressed in GC tissues and promoted GC progression in vitro via repressing the function of FBXW7 by binding it to the 3'-UTR of FBXW7. Conversely, restoration of FBXW7 remarkably inhibited the proliferation, invasion, and migration of GC cells [129] (Table 1). The overexpression of miR-223 in gastric cancer cells also attenuated the level of FBXW7, thereby increasing the GC cell proliferation, invasion and induced chemoresistance to trastuzumab in vitro [80,186]. Furthermore, in vitro and in vivo overexpression of FBXW7 in GC was found to markedly induce apoptosis and inhibited EMT by binding and degrading Ras homologue gene family, member A (RhoA), thereby manifesting its tumor suppressive action in GC [130].

6.6. Gynecological Cancers

FBXW7 has been reported to be mutated in at least 16% of human endometrial tumors. These mutations reside predominantly at the substrate-binding domain or at the amino-terminal region of the protein [20]. Gu et al. reported a missense mutation in SKOV3 ovarian cancer cells line with repressed FBXW7 [104] (Table 1). In cervical cancer, there is a marked upregulation of microRNA miR-92a, which binds to 3'UTR of the FBXW7 and inhibits the expression of FBXW7, thus promoting tumor progression and invasion [83]. When HeLa cervical cancer cells were treated with MAPK pathway inhibitor UO-126, FBXW7 expression was remarkably increased, indicating the involvement of FBXW7 in suppressing HeLa cell proliferation [187].

6.7. Hepatocellular Carcinoma (HCC)

In hepatocellular carcinoma (HCC), the mutation frequency of FBXW7 ranges from 27.8% to 50% in a particular case studied [142]. Studies have found downregulation of FBXW7 in HCC tissues compared to their adjacent tumor tissues, which may contribute to increased tumor size, and poor
prognosis [143,188]. Administration of recombinant human adenovirus-p53 (rAd-p5\Gendicine) in HCC significantly upregulated FBXW7 and downregulated its substrates c-Myc and cyclin E, resulting in the inhibition of cellular growth and apoptosis in vitro and in vivo [142]. It was further proven that FBXW7 instigated apoptosis in HCC in vitro and in vivo through ubiquitination and degradation of the oncoprotein Yes-associated protein (YAP) [143]. Further, studies have indicated that STAT1 exerted its tumor-suppressive role in HCC by upregulating p53 and FBXW7, which resulted in decreased expression of their downstream targets including cyclin A, cyclin D1, cyclin E, CDK2, Hes-1, and NF-κB p65. [144]. Hence, FBXW7 may serve as a potential target for the treatment of HCC patients [142] (Table 1).

6.8. Leukemia

Missense FBXW7 mutation has been reported in T cell acute lymphoblastic leukemia (T-ALL) as well as in B-cell acute lymphocytic leukemia [90,189]. FBXW7 mutation is found in 8–12% of T-ALL patients [190]. T-ALL patients with mutations in FBXW7 produced an elevated amount of Notch1, c-Myc and cyclin E [81,90,190–192]. Additionally, oncogenic transcription factor TAL1/SCL is abnormally expressed in T-ALL cells and led to an up-regulation of miR-223, which in turn significantly reduced FBXW7 and eventually conferred a marked increase of its oncogenic clients including c-Myc, Notch1, and cyclin E. [138]. On the contrary, it has been also reported that in primary T-ALL, loss of function of FBXW7 resulted in upregulation of glucocorticoid receptor α (GRα), enhancing glucocorticoids sensitivity. This increase in sensitivity can enhance the glucocorticoid treatment response, providing a favorable prognosis in T-ALL patients [137].

Remarkably, two FBXW7 mutants, D510E and D527G exhibited oncogenic function in the presence of HTLV-I Tax, mutated p53 R276H, or c-Myc F138C in T-cell leukemia (ATL). Studies showed that in ATL cases, mutated FBXW7 acts as an oncogene and holds a crucial role in the pathogenesis of ATL in part by losing their ability to bind to Notch1, thereby resulting in increased Notch1 signaling [139]. The increased NOTCH signaling further imparted resistance to gamma-secretase inhibitors (GSI) in T-ALL cells [133]. Recent studies showed that in ATL cases, the reduced expression of FBXW7 caused an increased expression of c-Myc and was associated with poorer prognosis [193]. Interestingly, a natural diterpenoid, oridonin exhibited its anti-cancer activity in leukemia in vitro and in vivo by promoting the FBXW7-mediated ubiquitin-proteasomal degradation of c-Myc [136]. Further, FBXW7 promoted apoptosis in T-All cells in vitro by ubiquitylating and degrading a pro-survival protein, MCL-1 [135]. Similarly, in activated B-cell like diffuse large B-cell lymphoma (ABC-DLBCL), exogenous overexpression of FBXW7 instigated apoptosis by inducing proteasomal degradation of signal transducer and activator of transcription 3 (STAT3), thus offering a novel approach for the treatment of ABC-DLBCL patients [140] (Table 1).

6.9. Lung Cancer

According to the TCGA data analysis, mutation frequency of FBXW7 was found to be 2.2% in 507 lung adenocarcinoma cases studied and 4.7% in lung squamous cell cancer cases studied which remarkably resulted in downregulation of FBXW7 leading to a poorer prognosis of lung cancer patients [86,194]. In support to this, in vitro and in vivo silencing of FBXW7 in non-small cell lung cancer (NSCLC) can significantly trigger EMT, promote migration and invasion and confer resistance to gefitinib treatment [151]. In lung adenocarcinoma patient, mutation of FBXW7 resulted in upregulation of mTOR [195]. Further, it has been revealed that the oncogenic activity of miR-367 is mediated in NSCLC cells by degrading its downstream target FBXW7, which eventually assisted in maintaining the activation of Wnt signaling [148]. Another report has shown that Akt inhibitor, API-1 (4-amino-5,8-dihydrro-5-oxo-8-β-D-ribofuranosyl-pyrido[2,3-d]pyrimidine-6-carboxamide) can induce apoptosis in lung cancer cells by triggering FBXW7-mediated degradation of MCL-1 [145]. Additionally, terminal differentiation-induced lncRNA (TINCR) was found to inhibit lung cancer cell proliferation and invasion by sequestering miR-544a from its target FBXW7, which caused an increased
upregulation of FBXW7. Moreover, a recent study has indicated that overexpression of FBXW7α mediated oncogenic transcription factor Cys2His2 zinc-finger 322A (ZNF322A) for degradation, thereby inhibiting ZNF322A-induced lung cancer progression in vitro and in vivo [147] (Table 1). Hence, these studies indicate the important function of FBXW7 in inhibiting lung cancer development and progression.

6.10. Pancreatic Cancer

In pancreatic adenocarcinoma, it has been found that mutations in FBXW7 at the exons 8 and 9 can induce upregulation of cyclin E [196]. In vitro silencing of FBXW7 significantly enhanced pancreatic cancer (PC) cell proliferation, migration, and invasion and rendered resistance to gemcitabine and nab-paclitaxel due to the accumulation of MCL1 [156] (Table 1). It has been demonstrated that in pancreatic ductal adenocarcinoma (PDAC), the nuclear exporter protein CRM1/Exportin 1/Xpo1 is highly expressed which can inhibit the activity of nuclear FBXW7, thereby enhancing the amount of nuclear Notch1. Studies have found that the anti-cancer activity of specific inhibitors of nuclear export (SINE) such as KPT-185 in Colo-357 PDAC xenografts is partly due to the accumulation of nuclear FBXW7 and subsequent degradation of Notch-1, c-Myc, and VEGF. Additionally, studies have found that FBXW7 directs β-catenin for its degradation, thereby disrupting Wnt/β-catenin signaling pathway. Due to the downregulation of FBXW7 in PC cells, the Wnt/β-catenin signaling pathway is aberrantly activated leading to the progression of PC. Thus, this study showed that by overexpressing FBXW7, its tumor suppressive action may be executed on PC cell through degradation of β-catenin [155].

6.11. Prostate Cancer

In prostate cancer, examining the expression level of FBXW7 is associated with the disease state and recurrence making it an important biomarker for determining the efficacy of proteasome target therapy [197]. In prostatic small cell neuroendocrine carcinoma (SCNC) mutations in p53 induced overexpression of miR-25 and inhibited FBXW7. This inhibition of FBXW7 resulted in upregulation of aurora kinase A which directs cancer cells proliferation and aggressive behavior of prostate SCNC [198].

6.12. Renal Cancer

In renal cancer patients, the expression of the FBXW7 was found to be aberrated by a constitutional t(3;4)(q21;q31) and is suspected to partake in the development of renal cell carcinoma (RCC) [24]. In RCC, upregulation of FBXW7 can lower the level of c-Myc and c-Jun, thereby reducing the proliferation rate of renal cancer cells and further prompted apoptosis [158]. Further, upregulation FBXW7 in 86-O and ACHN RCC cells can considerably inhibit metastasis and EMT via downregulating metalloproteinase (MMP)-2, MMP-9, and MMP-13 expression [159] (Table 1). Wilms’ tumor (WT) is one the most prevalent pediatric renal tumor wherein FBXW7 is either mutated or deleted in roughly 4% of tumors examined which resulted in the amplification of its target, Myc family, MYCN [199].

6.13. Skin Cancer

In skin cancer, studies found that allele-specific deletion of FBXW7 is observed in 7,12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA) induced skin tumor in mice [17]. An in vivo allele-specific deletion of FBXW7 is considered as the germline modifier of tumor susceptibility [29]. In UV-induced skin cancer, FBXW7α transcripts are reduced, and c-Jun is stabilized. This denotes that deregulation of FBXW7 is involved in the development of skin cancer [17]. Interestingly, Ishikawa et al. reported that FBXW7 may not be simply a tumor suppressor as it was found to exhibit two conflicting roles in skin carcinogenesis, i.e., it may either inhibit or promote tumor formation via degrading c-Myc or Notch respectively [160]. Aydin et al. demonstrated that inactivation of FBXW7 is observed in melanoma cells that causes accumulation of Notch1, thereby promoting angiogenesis [161] (Table 1). Reports have suggested
that FBXW7 expression is remarkably lower in primary melanoma than in dysplastic nevi and further lowered in the metastatic state compared to primary melanoma and its reduced expression is associated with poor 5-year survival of melanoma patients. Further, in vitro studies have revealed that FBXW7-inhibited melanoma cell migration via the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway. Thus, ablation of FBXW7 in melanoma cells leads to increased cell migration and stress fiber formation [15]. Moreover, FBXW7 was also found to regulate the oncogene MITF in melanoma. In vitro silencing of FBXW7 in melanoma considerably enhanced MITF/PGC-1 signaling contributing to the augmentation of mitochondrial transcription program and may result in poor outcomes for the patients [163] (Table 1).

6.14. Other Cancers

Studies have shown that in cholangiocarcinoma patients with low expression of FBXW7, upregulation of c-Myc and Ki-67 is observed with larger tumor size compared to those with higher FBXW7 expression [118]. Moreover, deficiency of FBXW7 was found to induce metastasis in cholangiocarcinoma cells via promoting EMT in vitro and in vivo [117]. In intrahepatic cholangiocarcinoma (IHCC), FBXW7 downregulation is directly linked with lymph nodes metastasis and poorer prognosis with 3 years survival rates of 29.4% than those with high expression of FBXW7 with 3 years survival rates of 72.7%. Thus, FBXW7 expression has potential as an independent prognostic marker for cholangiocarcinoma [200]. In the case of cervical cancer, cases with low expression of FBXW7 exhibited poor overall survival [201]. In osteosarcoma tissues, it has been shown that FBXW7 is downregulated compared to normal bone tissues. Moreover, in vitro and in vivo overexpression of FBXW7 in osteosarcoma strikingly instigated apoptosis and inhibited tumor progression via the degradation of c-Myc and cyclin E [27] (Table 1). It has also been elucidated that in bone marrow-derived stromal cells (BMSCs), loss of FBXW7 induced cancer metastasis via upregulation of the chemokine CCL2, which increased the monocytic myeloid-derived suppressor cells (Mo-MDSCs) as well as tumor-associated macrophages (TAMs) [34]. In oral cancer, low expression of FBXW7 was found to be associated with poor prognosis. Further, studies have revealed that miR-24 can potentiate the proliferation and metastasis in human tongue squamous cell carcinoma via inhibiting FBXW7 expression by binding to its 3-UTR [152,153]. Overall, these studies suggest the potential of FBXW7 as a prognostic marker and its importance as a tumor suppressor for the development of novel and effective therapy for cancer patients.

7. Role of FBXW7 in Cancer Cell Chemosensitization

Accumulated evidence has suggested that inactivation or downregulation of FBXW7 may lead to the development of chemoresistance in various cancers, such as breast cancer, colorectal cancer, gastric cancer, and non-small cell lung cancer (Table 2). Hence, activation or upregulation of FBXW7 has been indicated to overcome chemoresistance and sensitize the cancer cells to chemotherapies and increased the therapeutic efficacy of the existing treatments. On the contrary, Takeishi et al. suggested that expression of FBXW7 has implications in cancer drug resistance and that ablation of FBXW7 in combination with anti-cancer drugs might be a promising therapeutic strategy for chronic myeloid leukemia (CML) patients. For instance, CML, the leukemia-initiating cells (LICs) remained quiescent due to the reduced level of c-Myc caused by FBXW7 as a result of which the disease often relapses. However, ablation of FBXW7 reduced the quiescence of LIC and enhances their sensitivity to imatinib drug treatment [202].
Table 2. Role of FBXW7 in cancer cell chemosensitization.

| Cancer        | Combination     | In Vitro/In Vivo | Mechanism of Action | Ref. |
|---------------|-----------------|------------------|---------------------|------|
| Breast        | ↑FBXW7+ paclitaxel | In vitro         | ↓MCL-1; ↑PLK-1      | [113]|
| Colorectal    | ↑FBXW7+ doxorubicin | In vitro         | ↓EMT                | [126]|
|               | ↓FBXW7+ irinotecan | In vitro         | ↑c-Myc; ↓CSC        | [203]|
| CML           | ↓FBXW7+ imatinib  | In vivo          | ↓LICs               | [202]|
| Gastric       | ↑FBXW7+ trastuzumab | In vitro         | ↓MCL-1; ↓c-Myc; ↓c-Jun | [186]|
| Glioblastoma  | ↑FBXW7+ temozolomide | In vitro         | ↓Aurora B; ↓MCL-1; ↓Notch-1 | [106]|
| Liver         | ↑FBXW7+ doxorubicin | In vitro         | ↓EMT                | [204]|
| Lung          | ↑FBXW7+ cisplatin | In vitro         | ↓EMT                | [205]|
| Lung          | ↑FBXW7+ TKI      | In vitro         | ↓MCL-1              | [149]|
| Lung          | ↑FBXW7+ TKI      | In vivo          | ↓MCL-1              | [149]|
| Nasopharynx   | ↑FBXW7+ cisplatin | In vitro         | ↓MRP                | [206]|
| Pancreas      | ↑FBXW7+ gemcitabine | In vitro         | ↓ENT1               | [157]|

CSCs: cancer stem cell; EMT: Epithelial–mesenchymal transition; ENT: equilibrative nucleoside transporter 1; LICs: leukemia-initiating cells; MCL-1: Myeloid cell leukemia 1; MRP: multidrug resistance-associated protein; PLK-1: Polo-like kinase 1; TKI: tyrosine kinase inhibitors.

Further, it is well established that eliminating cancer stem cells (CSCs) is a promising approach for enhancing the efficacy of anticancer agents. Evidently, studies have found that FBXW7 is upregulated in colorectal CSCs which led to the acquisition of chemoresistance. However, in vitro knockdown of upregulated FBXW7 can enhance the efficacy of chemotherapeutic drugs including irinotecan, thus offering a feasible approach for obliterating colorectal CSCs [203].

On the other hand combination of FBXW7 overexpression with chemotherapeutic drug temozolomide notably sensitized the glioblastoma cells to temozolomide via downregulating Aurora B, MCL-1 and Notch-1, thereby signifying its potential as a target for therapy [106]. Moreover, downregulation of FBXW7 in MDA-MB-468R breast cancer cell induced resistance to the drug paclitaxel by the accumulation of its substrates myeloid cell leukemia 1 (MCL-1) and polo-like kinase 1 (PLK1). However, in vitro upregulation of FBXW7 significantly chemosensitized MDA-MB-468R cells to paclitaxel treatment [113]. In HCC, in vitro silencing of FBXW7 was found to impart resistance against doxorubicin, however, induced overexpression of FBXW7 significantly chemosensitized the HCC cells to doxorubicin by suppressing the EMT [204]. In CRC, an increase in the level of FBXW7 expression was directly associated with increased doxorubicin sensitivity in vitro. Moreover, it has also been reported that inactivation of miR-223 in CRC LoVo cells upregulated FBXW7 which enhanced the chemosensitivity of LoVo cells to doxorubicin by reducing the EMT [126]. Similarly, in GC it has been shown that inhibition of miR-223 restored the expression of FBXW7 and enhanced the trastuzumab-induced apoptosis [186]. Further, EMT is one of the prime factors accountable for the initiation of chemoresistance and FBXW7 has been found to notably partake in regulating the EMT in cancer cells [30]. Studies have indicated that non-small cell lung cancer (NSCLC) cells with low expression of FBXW7, such as NCI-H1299 cells, exhibited mesenchymal phenotype and are more resistant to cisplatin than cells with an epithelial phenotype. However, upregulation of FBXW7 markedly enhanced the sensitivity of NSCLC cells to chemotherapeutic drugs including cisplatin via modulation of EMT [205]. Additionally, FBXW7 was found to be downregulated in EGFR inhibitor-resistant NSCLC and reactivation of FBXW7 was found to sensitize the NSCLC cells to targeted therapy by facilitating the degradation of MCL-1 [149]. Interestingly, another study showed that although silencing of FBXW7 in NSCLC mediated taxol resistance, it also enhanced the sensitivity to a class I-specific histone deacetylase (HDAC) inhibitor, MS-275 which then eliminated the taxol resistance [146]. Further, in pancreatic cancer (PC), it has also been demonstrated that upregulation of FBXW7 substantially enhanced the chemosensitivity of the PC cells to gemcitabine via increased expression of equilibrative nucleoside transporter 1 (ENT1) [157]. Additionally, in nasopharyngeal...
Cancers 2019, 11, 246 18 of 31
carcinoma (NPC) cells, multidrug resistance-associated protein (MRP) was found to enhance the resistance of FBXW7-deficient NPC cells to cisplatin. Conversely, increased expression of FBXW7 remarkably induced chemosensitivity in these cells by downregulation of MRP [206]. Collectively, the majority of the studies suggest FBXW7 as a chemosensitizer that aids in overcoming chemoresistance for better and effective treatment of cancer patients.

8. Conclusions and Future Perspective

FBXW7, a crucial component of ubiquitin ligase SCF complex is a potent tumor suppressor that maintains the expression level of various growth regulator proteins by assisting them to the ubiquitin proteasomal system (UPS) for degradation, thereby preventing unregulated cell growth and tumorigenesis. However, FBXW7 is mutated or its pathway is perturbed in many human malignancies including colorectal, leukemia, breast, brain, ovary, cervical, ovary, endometrial, prostate, and gastric. Recent studies have demarcated the close association between mutation of FBXW7 and cancer progression as well as the role of FBXW7 in chemoresistance, which open up a new standpoint regarding the curative potential of targeted therapy. Hence, detection of the mutation status of the FBXW7 may serve as a suitable diagnostic biomarker and also play an invaluable factor in determining suitable individualized therapy [70,130]. As FBXW7 mutations are often heterozygote, determining the effect of monomeric and dimeric forms of FBXW7 on its mutational status is imperative for further understanding of FBXW7 function [207]. Moreover, in-depth studies must be carried out for elucidating the complex network of FBXW7 and its substrates and regulators which would further cater a clearer understanding of the pathogenesis of cancer and possibly finding out novel targets for effective treatment of cancer [201]. Several studies have indicated that induced overexpression of FBXW7 has the potential to chemosensitize cancer cells to chemotherapies. Nevertheless, studies have also found its implication in chemoresistance, implying the need for further studies. In addition, among the many substrates of FBXW7, the ones specifically involved in inducing chemoresistance has yet to be revealed [30]. Hence, despite the numerous studies on FBXW7, its role in cancer drug resistance remains questionable, recommending further elucidation.

Author Contributions: A.B.K. and G.S. conceived the idea and framework of the review. B.L.S. and D.B. collected the relevant literatures and drafted the manuscript. K.B. and S.G. contributed in the preparation of the tables and figures. L.F., C.E.H., H.W., A.P.K., D.Z. and X.M. edited the manuscript. All authors read and approved the final manuscript.

Funding: The work was supported by the Department of Biotechnology, Government of India—BT/556/NE/U-EXCEL/2016 dated 31.03.2017 awarded to Dr. Ajaikumar B. Kunnumakkara. This work was also supported by Ministry of Education Tier I grant (R-184-000-273-114) to GS.

Acknowledgments: The author Bethsebie Lalduhsaki Sailo acknowledges DST- INSPIRE, India for providing her with the fellowship. The author Kishore Banik acknowledges the UGC New Delhi, India for providing the fellowship.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| ABC-DLBCL   | Activated B-cell like diffuse large B-cell lymphoma |
| API-1        | 4-amino-5,8-dihydro-5-oxo-8-β-D-ribofuranosyl-pyrido[2,3-d]pyrimidine-6-carboxamide |
| ATL          | T-cell leukemia |
| BMSCs        | Bone marrow-derived stromal cells |
| C/EBP-δ      | CCAAT/enhancer-binding protein-δ |
| circRNAs     | Circular RNAs |
| CML          | Chronic myeloid leukemia |
| CPD          | Cdc4 phosphodegron |
| CRC          | Colorectal cancer |
| CSCs         | Cancer stem cells |
| Cul1         | Cul1 |

ABC-DLBCL Activated B-cell like diffuse large B-cell lymphoma
API-1 4-amino-5,8-dihydro-5-oxo-8-β-D-ribofuranosyl-pyrido[2,3-d]pyrimidine-6-carboxamide
ATL T-cell leukemia
BMSCs Bone marrow-derived stromal cells
C/EBP-δ CCAAT/enhancer-binding protein-δ
circRNAs Circular RNAs
CML Chronic myeloid leukemia
CPD Cdc4 phosphodegron
CRC Colorectal cancer
CSCs Cancer stem cells
Cul1 Cul1
| Term          | Definition                                                                 |
|--------------|---------------------------------------------------------------------------|
| DMBA         | 7,12-dimethylbenz[a]anthracene                                            |
| DNMT1        | DNA methyltransferase 1                                                   |
| EGLN2        | Egl-9 Family Hypoxia-Inducible Factor 2                                   |
| EMT          | Epithelial–mesenchymal transition                                         |
| ENO1         | Enolase 1                                                                 |
| ENT1         | Equilibrative nucleoside transporter 1                                    |
| EOGC         | Early-onset of gastric cancers                                            |
| ERK          | Extracellular signal-regulated kinase                                     |
| ESCC         | Esophageal squamous cell carcinoma                                         |
| ESCs         | Embryonic stem cells                                                      |
| EZH2         | Enhancer of zeste homolog 2 polycomb repressive complex 2                 |
| FAM83D       | Family with sequence similarity 83, member D                              |
| FBXL         | F-box coupled with LRRs                                                   |
| FBXO         | F-box with no motifs                                                      |
| FBXW         | F-box coupled with WD repeats                                             |
| FBXW7        | F-box with 7 tandem WD40 repeats                                           |
| GC           | Gastric cancer                                                            |
| GSI          | Gamma-secretase inhibitors                                                |
| GSK3         | Glycogen synthase kinase 3                                                |
| HDAC         | Histone deacetylase                                                       |
| Hes-5        | Hairy and Enhancer-of-split homologues 5                                  |
| HIF-1α       | Hypoxia-inducible factor-1α                                               |
| HSF1         | Heat-shock factor 1                                                       |
| Hsp90        | Heat shock protein 9                                                      |
| IHCC         | Intrahepatic cholangiocarcinoma                                            |
| KLFs         | Kruppel-like factors                                                      |
| LiCs         | Leukemia-initiating cells                                                 |
| LRR          | Leucine-rich repeats                                                      |
| MALAT1       | Metastasis-associated lung adenocarcinoma transcript 1                    |
| MAPK         | Mitogen-activated protein kinase                                           |
| MCL-1        | Myeloid cell leukemia 1                                                   |
| MED13        | Mediator 13                                                               |
| miR-10b      | microRNA-10b                                                              |
| MiRNAs       | MicroRNAs                                                                 |
| MMP          | Metalloproteinase                                                         |
| Mo-MDSCs     | Monocytic myeloid-derived suppressor cells                                |
| MTDH         | Metadherin                                                                |
| mTOR         | Mammalian target of rapamycin                                              |
| NF1          | Neurofibromatosis type 1                                                  |
| NF-KB        | Nuclear factor kappa B                                                    |
| NPC          | Nasopharyngeal carcinoma                                                  |
| NRF1         | Nuclear factor E2-related factor 1                                        |
| NSC          | Neural stem cell                                                          |
| NSCLC        | Non-small cell lung cancer                                                |
| PC           | Pancreatic cancer                                                         |
| PDAC         | Pancreatic ductal adenocarcinoma                                          |
| Pin1         | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1                     |
| PLK1         | Polo-like kinase 1                                                        |
| RCC          | Renal cell carcinoma                                                      |
| RhoA         | Ras homologue gene family member A                                        |
| RhoGDI       | RHO guanosine diphosphate dissociation inhibitor;                         |
| Rictor       | Rapamycin-insensitive companion of mTOR                                    |
| SCF          | Skp1-Cullin1-F-box                                                        |
| SCNC         | Small cell neuroendocrine carcinoma                                       |
SINE Specific inhibitors of nuclear export
Skp1 S phase kinase-associated protein 1
STAT3 Signal transducer and activator of transcription 3
T-ALL T-cell acute lymphoblastic leukemia
TAMs Tumor-associated macrophages
TINCR Terminal differentiation-induced IncRNA
TNBC Triple-negative breast cancer
TPA 12-O-tetradecanoylphorbol-13-acetate
Ubc Ubiquitin-conjugating enzyme
UPS Ubiquitin-proteasome system
WT Wilms’ tumor
YAP Yes-associated protein
ZNF322A Zinc-finger 322A

References
1. Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. *Int. J. Cancer* 2015, 136, E359–E386. [CrossRef] [PubMed]
2. Zhao, E.; Maj, T.; Kryczek, I.; Li, W.; Wu, K.; Zhao, L.; Wei, S.; Crespo, J.; Wan, S.; Vatan, L.; et al. Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction. *Nat. Immunol.* 2016, 17, 93–99. [CrossRef] [PubMed]
3. Shabnam, B.; Padmavathi, G.; Banik, K.; Girisa, S.; Monisha, J.; Sethi, G.; Fan, L.; Wang, L.; Mao, X.; Kunnumakkara, A.B. Sorcin a Potential Molecular Target for Cancer Therapy. *Transl. Oncol.* 2018, 11, 1379–1389. [CrossRef] [PubMed]
4. Ranaware, A.M.; Banik, K.; Deshpande, V.; Padmavathi, G.; Roy, N.K.; Sethi, G.; Fan, L.; Kumar, A.P.; Kunnumakkara, A.B. Magnolol: A Neolignan from the Magnolia Family for the Prevention and Treatment of Cancer. *Int. J. Mol. Sci.* 2018, 19, 2362. [CrossRef] [PubMed]
5. Banik, K.; Harsha, C.; Bordoloi, D.; Laldzuhiski Sailo, B.; Sethi, G.; Leong, H.C.; Arfuso, F.; Mishra, S.; Wang, L.; Kumar, A.P.; et al. Therapeutic potential of gambogenic acid, a caged xanthone, to target cancer. *Cancer Lett.* 2018, 416, 75–86. [CrossRef] [PubMed]
6. Zhou, Z.; He, C.; Wang, J. Regulation mechanism of Fbxw7-related signaling pathways (Review). *Oncol. Rep.* 2015, 34, 2215–2224. [CrossRef] [PubMed]
7. Diaz, V.M.; de Herreros, A.G. F-box proteins: Keeping the epithelial-to-mesenchymal transition (EMT) in check. *Semin. Cancer Biol.* 2016, 36, 71–79. [CrossRef] [PubMed]
8. Zheng, N.; Zhou, Q.; Wang, Z.; Wei, W. Recent advances in SCF ubiquitin ligase complex: Clinical implications. *Biochim. Biophys. Acta* 2016, 1866, 12–22. [CrossRef] [PubMed]
9. Gong, J.; Cao, J.; Liu, G.; Huo, J.R. Function and mechanism of F-box proteins in gastric cancer (Review). *Int. J. Oncol.* 2015, 47, 43–50. [CrossRef] [PubMed]
10. Zheng, N.; Schulman, B.A.; Song, L.; Miller, J.J.; Jeffrey, P.D.; Wang, P.; Chu, C.; Koepp, D.M.; Elledge, S.J.; Pagano, M.; et al. Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex. *Nature* 2002, 416, 703–709. [CrossRef] [PubMed]
11. Wei, D.; Sun, Y. Small RING Finger Proteins RBX1 and RBX2 of SCF E3 Ubiquitin Ligases: The Role in Cancer and as Cancer Targets. *Genes Cancer* 2010, 1, 700–707. [CrossRef] [PubMed]
12. Kipreos, E.T.; Pagano, M. The F-box protein family. *Genome Biol.* 2000, I. [CrossRef] [PubMed]
13. Davis, R.J.; Welcker, M.; Clurman, B.E. Tumor suppression by the Fbw7 ubiquitin ligase: Mechanisms and opportunities. *Cancer Cell* 2014, 26, 455–464. [CrossRef] [PubMed]
14. Bailey, M.L.; Singh, T.; Mero, P.; Moffat, J.; Hieter, P. Dependence of Human Colorectal Cells Lacking the FBW7 Tumor Suppressor on the Spindle Assembly Checkpoint. *Genetics* 2015, 201, 885–895. [CrossRef] [PubMed]
15. Cheng, Y.; Chen, G.; Martinka, M.; Ho, V.; Li, G. Prognostic significance of Fbw7 in human melanoma and its role in cell migration. *J. Investig. Dermatol.* 2013, 133, 1794–1802. [CrossRef] [PubMed]
16. Takeishi, S.; Nakayama, K.I. Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. *Br. J. Cancer* **2014**, *111*, 1054–1059. [CrossRef] [PubMed]

17. Xie, C.M.; Wei, W.; Sun, Y. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer. *J. Genet. Genom.* **2013**, *40*, 97–106. [CrossRef] [PubMed]

18. Zhao, J.; Tang, J.; Men, W.; Ren, K. FBXW7-mediated degradation of CCDC6 is impaired by ATM during DNA damage response in lung cancer cells. *FEBS Lett.* **2012**, *586*, 4257–4263. [CrossRef] [PubMed]

19. Akhoondi, S.; Lindstrom, L.; Widschwendter, M.; Corcoran, M.; Bergh, J.; Spruck, C.; Grander, D.; Sangfelt, O. Inactivation of FBXW7 and CDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. *Breast Cancer Res.* **2010**, *12*, R105. [CrossRef] [PubMed]

20. Spruck, C.H.; Strohmaier, H.; Sangfelt, O.; Muller, H.M.; Hubalek, M.; Muller-Holzner, E.; Marth, C.; Widschwendter, M.; Reed, S.I. hCDC4 gene mutations in endometrial cancer. *Cancer Res.* **2002**, *62*, 4535–4539. [PubMed]

21. Busino, L.; Millman, S.E.; Scotto, L.; Kyratsous, C.A.; Basrur, V.; O’Connor, O.; Hoffmann, A.; Elenitoba-Johnson, K.S.; Pagano, M. Fbxw7alpha- and GSK3-mediated degradation of p100 is a pro-survival mechanism in multiple myeloma. *Nat. Cell Biol.* **2012**, *14*, 375–385. [CrossRef] [PubMed]

22. Xu, Y.; Swartz, K.L.; Siu, K.T.; Bhattacharyya, M.; Minella, A.C. Fbw7-dependent cyclin E regulation ensures terminal maturation of bone marrow erythroid cells by restraining oxidative metabolism. *Oncogene* **2014**, *33*, 3161–3171. [CrossRef] [PubMed]

23. Matsuoka, S.; Oike, Y.; Onoyama, I.; Iwatsuki, M.; Ishii, H.; Onoyama, I.; Fukagawa, T.; Kuwano, H.; Nakayama, K.I.; Mori, M. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. *Cancer Res.* **2009**, *69*, 3788–3794. [CrossRef] [PubMed]

24. Kuiper, R.P.; Vreede, L.; Venkatachalam, R.; Ricketts, C.; Kamping, E.; Verwiel, E.; Govaerts, L.; Debiec-Rychter, M.; Lerut, E.; van Erp, F.; et al. The tumor suppressor gene FBXW7 is disrupted by a constitutional t(3;4)(q21;q31) in a patient with renal cell cancer. *Cancer Genet. Cytogenet.* **2009**, *195*, 105–111. [CrossRef] [PubMed]

25. Yokobori, T.; Mimori, K.; Iwatsuki, M.; Ishii, H.; Onoyama, I.; Fukagawa, T.; Kuwano, H.; Nakayama, K.I.; Mori, M. p33-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. *Cancer Res.* **2009**, *69*, 3788–3794. [CrossRef] [PubMed]

26. Perez-Losada, J.; Wu, D.; DelRosario, R.; Balmain, A.; Mao, J.H. Allele-specific deletions in mouse tumors identify Fbxw7 as a germline modifier of tumor susceptibility. *PLoS ONE* **2012**, *7*, e31301. [CrossRef] [PubMed]

27. Jardim, D.L.; Wheler, J.J.; Hess, K.; Tsimberidou, A.M.; Balmain, A.; Bandapalli, O.R.; Rajkumar, T.; Sagar, T.G.; Karunakaran, N. NOTCH1 and FBXW7 mutations favor better outcome in pediatric South Indian T-cell acute lymphoblastic leukemia. *J. Pediatr. Hematol. Oncol.* **2015**, *37*, e23–e30. [CrossRef] [PubMed]

28. Sethi, G.; Tergaonkar, V. Potential pharmacological control of the NF-kappaB pathway. *Trends Pharmacol. Sci.* **2009**, *30*, 313–321. [CrossRef] [PubMed]
36. Li, F.; Sethi, G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. *Biochim. Biophys. Acta* 2010, 1805, 167–180. [CrossRef] [PubMed]

37. Sethi, G.; Shanmugam, M.K.; Ramachandran, L.; Kumar, A.P.; Tergaonkar, V. Multifaceted link between cancer and inflammation. *Biosci. Rep.* 2012, 32, 1–15. [CrossRef] [PubMed]

38. Li, F.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. NF-kappaB in cancer therapy. *Arch. Toxicol.* 2015, 89, 711–731. [CrossRef] [PubMed]

39. Chai, E.Z.; Siveen, K.S.; Shanmugam, M.K.; Arfuso, F.; Sethi, G. Analysis of the intricate relationship between chronic inflammation and cancer. *Biochem. J.* 2015, 468, 1–15. [CrossRef] [PubMed]

40. Ahn, K.S.; Sethi, G.; Aggarwal, B.B. Nuclear factor-kappa B: From clone to clinic. *Curr. Mol. Med.* 2007, 7, 619–637. [CrossRef] [PubMed]

41. Puar, Y.R.; Shanmugam, M.K.; Fan, L.; Arfuso, F.; Sethi, G.; Tergaonkar, V. Evidence for the Involvement of the Master Transcription Factor NF-kappaB in Cancer Initiation and Progression. *Biomedicines* 2018, 6, 82. [CrossRef] [PubMed]

42. Shanmugam, M.K.; Ahn, K.S.; Lee, J.H.; Kannaiyan, R.; Mustafa, N.; Manu, K.A.; Siveen, K.S.; Sethi, G.; Chng, W.J.; Kumar, A.P. Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. *Front. Pharmacol.* 2018, 9, 365. [CrossRef] [PubMed]

43. Manu, K.A.; Shanmugam, M.K.; Ramachandran, L.; Li, F.; Siveen, K.S.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Arfuso, F.; Kumar, A.P.; et al. Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-kappaB signaling cascade in gastric cancer. *Cancer Lett.* 2015, 363, 28–36. [CrossRef] [PubMed]

44. Li, F.; Shanmugam, M.K.; Siveen, K.S.; Wang, F.; Ong, T.H.; Loo, S.Y.; Swamy, M.M.; Mandal, S.; Kumar, A.P.; Goh, B.C.; et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. *Oncotarget* 2015, 6, 5147–5163. [CrossRef] [PubMed]

45. Shanmugam, M.K.; Ahn, K.S.; Hsu, A.; Woo, C.C.; Yuan, Y.; Tan, K.H.B.; Chinnathambi, A.; Alahmadi, T.A.; Alharbi, S.A.; Koh, A.P.F.; et al. Thymoquinone Inhibits Bone Metastasis of Breast Cancer Cells Through Abrogation of the CXCR4 Signaling Axis. *Front. Pharmacol.* 2018, 9, 1294. [CrossRef] [PubMed]

46. Mohan, C.D.; Bharathkumar, H.; Dukanya, D.; Rangappa, S.; Shanmugam, M.K.; Chinnathambi, A.; Alharbi, S.A.; Alahmadi, T.A.; Bhattacharjee, A.; Lobie, P.E.; et al. N-Substituted Pyrido-1,4-Oxazin-3-Ones Induce Apoptosis of Hepatocellular Carcinoma Cells by Targeting NF-kappaB Signaling Pathway. *Front. Pharmacol.* 2018, 9, 1125. [CrossRef] [PubMed]

47. Liu, L.; Ahn, K.S.; Shanmugam, M.K.; Wang, H.; Shen, H.; Arfuso, F.; Chinnathambi, A.; Alharbi, S.A.; Chang, Y.; Sethi, G.; et al. Oleuropein induces apoptosis via abrogating NF-kappaB activation cascade in estrogen receptor-negative breast cancer cells. *J. Cell. Biochem.* 2019, 120, 4504–4513. [CrossRef] [PubMed]

48. Ningegowda, R.; Shivananju, N.S.; Rajendran, P.; Rangappa, K.S.; Chinnathambi, A.; Li, F.; Achar, R.R.; Shanmugam, M.K.; Bist, P.; Alharbi, S.A.; et al. A novel 4,6-disubstituted-1,2,4-triazolo-1,3,4-thiadiazole derivative inhibits tumor cell invasion and potentiates the apoptotic effect of TNFalpha by abrogating NF-kappaB activation cascade. *Apoptosis* 2017, 22, 145–157. [CrossRef] [PubMed]

49. Siveen, K.S.; Mustafa, N.; Li, F.; Kannaiyan, R.; Ahn, K.S.; Kumar, A.P.; Chng, W.J.; Sethi, G. Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-kappaB regulated gene products in multiple myeloma xenograft mouse model. *Oncotarget* 2014, 5, 634–648. [CrossRef] [PubMed]

50. Kim, C.; Cho, S.K.; Kim, K.D.; Nam, D.; Chung, W.S.; Jang, H.J.; Lee, S.G.; Shim, B.S.; Sethi, G.; Ahn, K.S. beta-Caryophyllene oxide potentiates TNFalpha-induced apoptosis and inhibits invasion through down-modulation of NF-kappaB-regulated gene products. *Apoptosis* 2014, 19, 708–718. [CrossRef] [PubMed]

51. Manu, K.A.; Shanmugam, M.K.; Li, F.; Chen, L.; Siveen, K.S.; Ahn, K.S.; Kumar, A.P.; Sethi, G. Simvastatin sensitizes human gastric cancer xenograft in nude mice to capecitabine by suppressing nuclear factor-kappa B-regulated gene products. *J. Mol. Med.* 2014, 92, 267–276. [CrossRef] [PubMed]

52. Li, F.; Shanmugam, M.K.; Chen, L.; Chatterjee, S.; Bashar, J.; Kumar, A.P.; Kundu, T.K.; Sethi, G. Garcinol, a polyisoprenylated benzophenone modulates multiple proinflammatory signaling cascades leading to the suppression of growth and survival of head and neck carcinoma. *Cancer Prev. Res.* 2013, 6, 843–854. [CrossRef] [PubMed]
53. Manu, K.A.; Shanmugam, M.K.; Ong, T.H.; Subramaniam, A.; Siveen, K.S.; Perumal, E.; Samy, R.P.; Bist, P.; Lim, L.H.; Kumar, A.P.; et al. Emodin suppresses migration and invasion through the modulation of CXCRI4 expression in an orthotopic model of human hepatocellular carcinoma. *PLoS ONE* 2013, 8, e57015. [CrossRef] [PubMed]

54. Shanmugam, M.K.; Ong, T.H.; Kumar, A.P.; Lun, C.K.; Ho, P.C.; Wong, P.T.; Hui, K.M.; Sethi, G. Ursolic acid inhibits the initiation, progression of prostate cancer and prolongs the survival of TRAMP mice by modulating pro-inflammatory pathways. *PLoS ONE* 2012, 7, e32476. [CrossRef] [PubMed]

55. Manu, K.A.; Shanmugam, M.K.; Ramachandran, L.; Li, F.; Fong, C.W.; Kumar, A.P.; Tan, P.; Sethi, G. First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemo-sensitizes it to capecitabine in a xenograft mouse model through the modulation of NF-kappaB pathway. *Clin. Cancer Res.* 2012, 18, 2220–2229. [CrossRef] [PubMed]

56. Akincilar, S.C.; Low, K.C.; Liu, C.Y.; Yan, T.D.; Oji, A.; Ikawa, M.; Li, S.; Tergaonkar, V. Quantitative assessment of telomerase components in cancer cell lines. *FERS Lett.* 2015, 589, 974–984. [CrossRef] [PubMed]

57. Khattar, E.; Kumar, P.; Liu, C.Y.; Akincilar, S.C.; Raju, A.; Lakshmanan, M.; Maury, J.J.; Qiang, Y.; Li, S.; Tan, E.Y.; et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. *J. Clin. Investig.* 2016, 126, 4045–4060. [CrossRef] [PubMed]

58. Liu, Y.; Tergaonkar, V.; Krishna, S.; Androphy, E.J. Human papillomavirus type 16 E6-enhanced susceptibility of L929 cells to tumor necrosis factor alpha correlates with increased accumulation of reactive oxygen species. *J. Biol. Chem.* 1999, 274, 24819–24827. [CrossRef]

59. Akinclilcar, S.C.; Low, K.C.; Liu, C.Y.; Yan, T.D.; Qiang, Y.; Li, S.; Tergaonkar, V. Quantitative assessment of telomerase components in cancer cell lines. *FERS Lett.* 2015, 589, 974–984. [CrossRef] [PubMed]

60. Khattar, E.; Kumar, P.; Liu, C.Y.; Akincilar, S.C.; Raju, A.; Lakshmanan, M.; Maury, J.J.; Qiang, Y.; Li, S.; Tan, E.Y.; et al. Telomerase reverse transcriptase promotes cancer cell proliferation by augmenting tRNA expression. *J. Clin. Investig.* 2016, 126, 4045–4060. [CrossRef] [PubMed]

61. Li, Y.; Cheng, H.S.; Chng, W.J.; Tergaonkar, V. Activation of mutant TERT promoter by RAS-ERK signaling is a key step in malignant progression of BRAF-mutant human melanomas. *Proc. Natl. Acad. Sci. USA* 2016, 113, 14402–14407. [CrossRef] [PubMed]

62. Arabi, A.; Ullah, K.; Branca, R.M.; Johansson, J.; Bandarra, D.; Haneklaus, M.; Fu, J.; Aries, I.; Nilsson, P.; Den Boer, M.L.; et al. Proteomic screen reveals Fbw7 as a modulator of the NF-kappaB pathway. *Nat. Commun.* 2012, 3, 976. [CrossRef] [PubMed]

63. Fukushima, H.; Matsumoto, A.; Inuzuka, H.; Zhai, B.; Lau, A.W.; Wan, L.; Gao, D.; Shaik, S.; Yuan, M.; Gygi, S.P.; et al. SCF(Fbw7) modulates the NFkB signaling pathway by targeting NFkB2 for ubiquitination and destruction. *Cell Rep.* 2012, 1, 434–443. [CrossRef] [PubMed]

64. Courtois, N.; Moubarak, R.; Aranda-Orgilles, B.; Lui, K.; Aydin, I.T.; Tramarchi, T.; Darvishian, F.; Salvaglio, C.; Zhong, J.; Bhatt, K.; et al. FBXW7 modulates cellular stress response and metastatic potential through HSF1 post-translational modification. *Nat. Cell Biol.* 2015, 17, 322–332. [CrossRef] [PubMed]

65. Zhang, Y.; Hao, J.; Zheng, Y.; Jing, D.; Shen, Y.; Wang, J.; Zhao, Z. Role of Kruppel-like factors in cancer stem cells. *J. Physiol. Biochem.* 2015, 71, 151–164. [CrossRef] [PubMed]

66. Wang, R.; Wang, Y.; Liu, N.; Ren, C.; Jiang, C.; Zhang, K.; Yu, S.; Chen, Y.; Tang, H.; Deng, Q.; et al. FBW7 regulates endothelial functions by targeting KLF2 for ubiquitination and degradation. *Cell Res.* 2013, 23, 803–819. [CrossRef] [PubMed]

67. Wei, W.; Jin, J.; Schlissel, S.; Harper, J.W.; Kaelin, W.G., Jr. The v-Jun point mutation allows c-Jun to escape GSK3-dependent recognition and destruction by the Fbw7 ubiquitin ligase. *Cancer Cell* 2005, 8, 25–33. [CrossRef] [PubMed]

68. Kimura, T.; Gotoh, M.; Nakamura, Y.; Arakawa, H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. *Cancer Sci.* 2003, 94, 431–436. [CrossRef] [PubMed]
70. Cao, J.; Ge, M.H.; Ling, Z.Q. Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis. *Medicine* **2016**, *95*, e2496. [CrossRef] [PubMed]

71. Balamurugan, K.; Sterneck, E. The many faces of C/EBPdelta and their relevance for inflammation and cancer. *Int. J. Biol. Sci.* **2013**, *9*, 917–933. [CrossRef] [PubMed]

72. Gery, S.; Tanosaki, S.; Hofmann, W.K.; Koppel, A.; Koeffler, H.P. C/EBPdelta expression in a BCR-ABL-positive cell line induces growth arrest and myeloid differentiation. *Oncogene* **2005**, *24*, 1589–1597. [CrossRef] [PubMed]

73. Welcker, M.; Clurman, B.E. FBW7 ubiquitin ligase: A tumour suppressor at the crossroads of cell division, growth and differentiation. *Nat. Rev. Cancer* **2008**, *8*, 83–93. [CrossRef] [PubMed]

74. Balamurugan, K.; Wang, J.M.; Tsai, H.H.; Sharan, S.; Anver, M.; Leighty, R.; Sterneck, E. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. *EMBO J.* **2010**, *29*, 4106–4117. [CrossRef] [PubMed]

75. Lu, K.P.; Zhou, X.Z. The prolyl isomerase PIN1: A pivotal new twist in phosphorylation signalling and disease. *Nat. Rev. Mol. Cell Biol.* **2007**, *8*, 904–916. [CrossRef] [PubMed]

76. Min, S.H.; Lau, A.W.; Lee, T.H.; Inuzuka, H.; Wei, S.; Huang, P.; Shaik, S.; Lee, D.Y.; Finn, G.; Balastik, M.; et al. Negative regulation of the stability and tumor suppressor function of Fbw7 by the Pin1 prolyl isomerase. *Mol. Cell* **2012**, *46*, 771–783. [CrossRef] [PubMed]

77. Jiang, X.; Xing, H.; Kim, T.M.; Jung, Y.; Huang, W.; Yang, H.W.; Song, S.; Park, P.J.; Carroll, R.S.; Johnson, M.D. Numb regulates glioma stem cell fate and growth by altering epidermal growth factor receptor and Skp1-Cullin-F-box ubiquitin ligase activity. *Stem Cells* **2012**, *30*, 1313–1326. [CrossRef] [PubMed]

78. Wang, Q.; Li, D.C.; Li, Z.F.; Liu, C.X.; Xiao, Y.M.; Zhang, B.; Li, X.D.; Zhao, J.; Chen, L.P.; Xing, X.M.; et al. Upregulation of miR-27a contributes to the malignant transformation of human bronchial epithelial cells induced by SV40 small T antigen. *Oncogene* **2011**, *30*, 3875–3886. [CrossRef] [PubMed]

79. Lerner, M.; Lundgren, J.; Akhoondi, S.; Jahn, A.; Ng, H.F.; Akbari Moqadam, F.; Oude Vrielink, J.A.; Koeffler, H.P. C/EBPdelta expression in a human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. *Gut* **2012**, *63*, 6–9. [CrossRef] [PubMed]

80. Li, J.; Guo, Y.; Liang, X.; Sun, M.; Wang, G.; De, W.; Wu, W. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. *J. Cancer Res. Clin. Oncol.* **2012**, *138*, 763–774. [CrossRef] [PubMed]

81. Kumar, V.; Palermo, R.; Talora, C.; Campese, A.F.; Checquolo, S.; Bellavia, D.; Tottone, L.; Testa, G.; Miele, E.; Indraccolo, S.; et al. Notch and NF-kB signaling pathways regulate miR-223/FBXW7 axis in T-cell acute lymphoblastic leukemia. *Leukemia* **2014**, *28*, 2324–2335. [CrossRef] [PubMed]

82. Xia, W.; Zhou, J.; Luo, H.; Liu, Y.; Peng, C.; Zheng, W.; Ma, W. MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7. *Cancer Cell Int.* **2014**, *14*, 37. [CrossRef] [PubMed]

83. Zhou, C.; Shen, L.; Mao, L.; Wang, B.; Li, Y.; Yu, H. miR-92a is upregulated in cervical cancer and promotes cell proliferation and invasion by targeting FBXW7. *Biochem. Biophys. Res. Commun.* **2015**, *458*, 63–69. [CrossRef] [PubMed]

84. Chang, H.; Liu, Y.H.; Wang, L.L.; Wang, J.; Zhao, Z.H.; Qu, J.F.; Wang, S.F. MiR-182 promotes cell proliferation by suppressing FBXW7 and FBXW11 in non-small cell lung cancer. *Am. J. Transl. Res.* **2018**, *10*, 1131–1142. [PubMed]

85. Akhoondi, S.; Sun, D.; von der Lehr, N.; Apostolidou, S.; Klotz, K.; Maljukova, A.; Cepeda, D.; Fiegli, H.; Dafou, D.; Marth, C.; et al. FBXW7/hCDC4 is a general tumor suppressor in human cancer. *Cancer Res.* **2007**, *67*, 9006–9012. [CrossRef] [PubMed]

86. Cerami, E.; Gao, J.; D’Ongruzzo, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.; Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2012**, *2*, 401–404. [CrossRef] [PubMed]

87. Mao, J.H.; Kim, I.J.; Wu, D.; Climent, J.; Kang, H.C.; DelRosario, R.; Balmain, A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. *Science* **2008**, *321*, 1499–1502. [CrossRef] [PubMed]

88. Davis, H.; Lewis, A.; Behrens, A.; Tomlinson, I. Investigation of the atypical FBXW7 mutation spectrum in human tumours by conditional expression of a heterozygous propellor tip missense allele in the mouse intestines. *Gut* **2014**, *63*, 792–799. [CrossRef] [PubMed]
89. Sancho, R.; Jandke, A.; Davis, H.; Diefenbacher, M.E.; Tomlinson, I.; Behrens, A. F-box and WD repeat domain-containing 7 regulates intestinal cell lineage commitment and is a haploinsufficient tumor suppressor. *Gastroenterology* 2010, 139, 929–941. [CrossRef] [PubMed]

90. King, B.; Trimarchi, T.; Reavie, L.; Xu, L.; Mullenders, J.; Nitschriostos, P.; Aranda-Orgilles, B.; Perez-Garcia, A.; Shi, J.; Vacok, C.; et al. The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. *Cell* 2013, 153, 1552–1566. [CrossRef] [PubMed]

91. Davis, H.; Lewis, A.; Spencer-Dene, B.; Tatsos, H.; Stamp, G.; Behrens, A.; Tomlinson, I. FBXW7 mutations typically found in human cancers are distinct from null alleles and disrupt lung development. *J. Pathol.* 2011, 224, 180–189. [CrossRef] [PubMed]

92. Kitade, S.; Onoyama, I.; Kobayashi, H.; Yagi, H.; Yoshida, S.; Kato, M.; Tsunematsu, R.; Asanoma, K.; Sonoda, K.; Wake, N.; et al. FBXW7 is involved in the acquisition of the malignant phenotype in epithelial ovarian tumors. *Cancer Sci.* 2016, 107, 1399–1405. [CrossRef] [PubMed]

93. Cremona, C.A.; Sancho, R.; Diefenbacher, M.E.; Behrens, A. Fbw7 and its counteracting forces in stem cells and cancer. Oncoproteins in the balance. *Semin. Cancer Biol.* 2016, 36, 52–61. [CrossRef] [PubMed]

94. Kunnumakkara, A.B.; Banik, K.; Bordoloi, D.; Harsha, C.; Sailo, B.L.; Padmavathi, G.; Roy, N.K.; Gupta, S.C.; Aggarwal, B.B. Googling the Guggul (Commiphora and Boswellia) for Prevention of Chronic Diseases. *Front. Pharmacol.* 2018, 9, 686. [CrossRef] [PubMed]

95. Kunnumakkara, A.B.; Sailo, B.L.; Banik, K.; Harsha, C.; Prasad, S.; Gupta, S.C.; Bharti, A.C.; Aggarwal, B.B. Chronic diseases, inflammation, and spices: How are they linked? *J. Transl. Med.* 2018, 16, 14. [CrossRef] [PubMed]

96. Bordoloi, D.; Banik, K.; Shabnam, B.; Padmavathi, G.; Monisha, J.; Arfuso, F.; Dharmarajan, A.; Mao, X.; Lim, L.H.K.; Wang, L.; et al. TIE Family of Proteins and Its Implications in Different Chronic Diseases. *Int. J. Mol. Sci.* 2018, 19, 2974. [CrossRef] [PubMed]

97. Kunnumakkara, A.B.; Sailo, B.L.; Banik, K.; Gupta, S.C.; Aggarwal, B.B. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. *Clin. Sci.* 2017, 131, 1781–1799. [CrossRef] [PubMed]

98. Khwairakpam, A.D.; Bordoloi, D.; Thakur, K.K.; Arfuso, F.; Sethi, G.; Mishra, S.; Kumar, A.P.; Kunnumakkara, A.B. Possible use of Punica granatum (Pomegranate) in cancer therapy. *Pharmacol. Res.* 2018, 133, 53–64. [CrossRef] [PubMed]

99. Wang, Y.; Liu, Y.; Lu, J.; Zhang, P.; Wang, Y.; Xu, Y.; Wang, Z.; Mao, J.H.; Wei, G. Rapamycin inhibits FBXW7 loss-induced epithelial-mesenchymal transition and cancer stem cell-like characteristics in colorectal cancer cells. *Biochem. Biophys. Res. Commun.* 2013, 434, 352–356. [CrossRef] [PubMed]

100. Yumimoto, K.; Akiyoshi, S.; Ueo, H.; Sagara, Y.; Onoyama, I.; Ohno, S.; Mori, M.; Mimori, K.; Nakayama, K.I. F-box protein FBXW7 inhibits cancer metastasis in a non-cell-autonomous manner. *J. Clin. Invest.* 2015, 125, 621–635. [CrossRef] [PubMed]

101. Teplyuk, N.M.; Uhlmann, E.J.; Wong, A.H.; Karmali, P.; Basu, M.; Gabriely, G.; Jain, A.; Wang, Y.; Chiocca, E.A.; Stephens, R.; et al. MicroRNA-10b inhibition reduces E2F1-mediated transcription and miR-15/16 activity by regulating MYC stability. *Oncotarget* 2015, 6, 3770–3783. [CrossRef] [PubMed]

102. Kim, H.S.; Woolard, K.; Lai, C.; Bauer, P.O.; Maric, D.; Song, H.; Li, A.; Kotliarova, S.; Zhang, W.; Fine, H.A. Gliomagenesis arising from Pten- and Ink4a/Arf-deficient neural progenitor cells is mediated by the p53-Fbxw7/Cdc4 pathway, which controls c-Myc. *Cancer Res.* 2015, 75, 2192–2212. [CrossRef] [PubMed]

103. Gu, Z.; Mitsui, H.; Inomata, K.; Honda, M.; Endo, C.; Sakurada, A.; Sato, M.; Okada, Y.; Kondo, T.; Horii, A. The methylation status of FBXW7 beta-form correlates with histological subtype in human thymoma. *Biochem. Biophys. Res. Commun.* 2008, 377, 685–688. [CrossRef] [PubMed]

104. Gu, Z.; Inomata, K.; Ishizawa, K.; Horii, A. The FBXW7 beta-form is suppressed in human glioma cells. *Biochem. Biophys. Res. Commun.* 2007, 354, 992–998. [CrossRef] [PubMed]

105. Surajo Rahmanto, A.; Savoy, V.; Bronner, A.; Bolin, S.; Weishaupt, H.; Malysukova, A.; Rosen, G.; Cancer, M.; Hutter, S.; Sundstrom, A.; et al. FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. *EMBO J.* 2016, 35, 2192–2212. [CrossRef] [PubMed]

106. Lin, J.; Ji, A.; Qiu, G.; Feng, H.; Li, J.; Li, S.; Zou, Y.; Cui, Y.; Song, C.; He, H.; et al. FBW7 is associated with prognosis, inhibits malignancies and enhances temozolomide sensitivity in glioblastoma cells. *Cancer Sci.* 2018, 109, 1001–1011. [CrossRef] [PubMed]
107. Cao, S.; Wang, Y.; Li, J.; Lv, M.; Niu, H.; Tian, Y. Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function. *Am. J. Cancer Res.* 2016, 6, 2561–2574. [PubMed]

108. Yang, Y.; Gao, X.; Zhang, M.; Yan, S.; Sun, C.; Xiao, F.; Huang, N.; Yang, X.; Zhao, K.; Zhou, H.; et al. Novel Role of FBXW7 Circular RNA in Repressing Glioma Tumorigenesis. *J. Natl. Cancer Inst.* 2018, 110. [CrossRef] [PubMed]

109. Zhao, D.; Zheng, H.Q.; Zhou, Z.; Chen, C. The Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated degradation and suppresses breast cell proliferation. *Cancer Res.* 2010, 70, 4728–4738. [CrossRef] [PubMed]

110. Ibusuki, M.; Yamamoto, Y.; Shinriki, S.; Ando, Y.; Iwase, H. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. *Cancer Sci.* 2011, 102, 439–445. [CrossRef] [PubMed]

111. Wang, Z.; Liu, Y.; Zhang, P.; Zhang, W.; Wang, W.; Curr, K.; Wei, G.; Mao, J.H. FAM83D promotes cell proliferation and motility by downregulating tumor suppressor gene FBXW7. *Oncotarget* 2013, 4, 2476–2486. [CrossRef] [PubMed]

112. Sun, Y.; Li, X. The canonical wnt signal restricts the glycogen synthase kinase 3/fbw7-dependent ubiquitination and degradation of eya1 phosphatase. *Mol. Cell. Biol.* 2014, 34, 2409–2417. [CrossRef] [PubMed]

113. Gasca, J.; Flores, M.L.; Giraldez, S.; Ruiz-Borrego, M.; Tortolero, M.; Romero, F.; Japon, M.A.; Saez, C. Loss of FBXW7 and accumulation of MCL1 and PLK1 promote paclitaxel resistance in breast cancer. *Oncotarget* 2016, 7, 52751–52765. [CrossRef] [PubMed]

114. Ma, L.M.; Liang, Z.R.; Zhou, K.R.; Zhou, H.; Qu, L.H. 27-Hydroxycholesterol increases Myc protein stability via suppressing PP2A, SCP1 and FBW7 transcription in MCF-7 breast cancer cells. *Biochem. Biophys. Res. Commun.* 2016, 480, 328–333. [CrossRef] [PubMed]

115. Takada, M.; Zhuang, M.; Inuzuka, H.; Zhang, J.; Zurlo, G.; Zhang, J.; Zhang, Q. EglN2 contributes to triple negative breast tumorigenesis by functioning as a substrate for the FBW7 tumor suppressor. *Oncotarget* 2017, 8, 6787–6795. [CrossRef] [PubMed]

116. Chen, X.; Li, X.Y.; Long, M.; Wang, X.; Gao, Z.W.; Cui, Y.; Ren, J.; Zhang, Z.; Liu, C.; Dong, K.; et al. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation. *Neoplasma* 2018, 65, 201–209. [CrossRef] [PubMed]

117. Yang, H.; Lu, X.; Liu, Z.; Chen, L.; Xu, Y.; Wang, Y.; Wei, G.; Chen, Y. FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells. *Oncotarget* 2015, 6, 6310–6325. [CrossRef] [PubMed]

118. Ishii, N.; Araki, K.; Yokobori, T.; Watanabe, A.; Tsukagoshi, M.; Kubo, N.; Suzuki, H.; Saito, F.; Altan, B.; Harauchi, Y.; et al. Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy. *Oncol. Lett.* 2017, 13, 3653–3661. [CrossRef] [PubMed]

119. Iwatsuki, M.; Mimori, K.; Ishii, H.; Yokobori, T.; Takatsuno, Y.; Sato, T.; Toh, H.; Onoyama, I.; Nakayama, K.I.; Baba, H.; et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: Clinical significance. *Int. J. Cancer* 2010, 126, 1828–1837. [CrossRef] [PubMed]

120. Ou, B.; Zhao, J.; Guan, S.; Wangpu, X.; Zhu, C.; Zong, Y.; Ma, J.; Sun, J.; Zheng, M.; Feng, H.; et al. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbw7/Cyclin E in colorectal cancer. *Cancer Lett.* 2016, 380, 457–466. [CrossRef] [PubMed]

121. Grim, J.E.; Knoeblaugh, S.E.; Guthrie, K.A.; Hagar, A.; Swanger, J.; Hespelt, J.; Delrow, J.J.; Small, T.; Grady, W.M.; Nakayama, K.I.; et al. Fbw7 and p53 cooperatively suppress advanced and chromosomally unstable intestinal cancer. *Mol. Cell. Biol.* 2012, 32, 2160–2167. [PubMed]

122. Zhan, P.; Wang, Y.; Zhao, S.; Liu, C.; Wang, Y.; Wen, M.; Mao, J.H.; Wei, G.; Zhang, P. FBXW7 negatively regulates ENO1 expression and function in colorectal cancer. *Lab. Invest.* 2015, 95, 995–1004. [CrossRef] [PubMed]

123. Ou, B.; Zhao, J.; Guan, S.; Wangpu, X.; Zhu, C.; Zong, Y.; Ma, J.; Sun, J.; Zheng, M.; Feng, H.; et al. Plk2 promotes tumor growth and inhibits apoptosis by targeting Fbw7/Cyclin E in colorectal cancer. *Cancer Lett.* 2016, 380, 457–466. [CrossRef] [PubMed]

124. Tong, J.; Tan, S.; Nikolovska-Coleska, Z.; Yu, J.; Zou, F.; Zhang, L. FBW7-Dependent Mcl-1 Degradation Mediates the Anticancer Effect of Hsp90 Inhibitors. *Mol. Cancer Ther.* 2017, 16, 1979–1988. [CrossRef] [PubMed]
125. Mu, Y.; Zou, H.; Chen, B.; Fan, Y.; Luo, S. FAM83D knockdown regulates proliferation, migration and invasion of colorectal cancer through inhibiting FBXW7/Notch-1 signalling pathway. *Biomed. Pharmacother.* 2017, 90, 548–554. [CrossRef] [PubMed]

126. Ding, J.; Zhao, Z.; Song, J.; Luo, B.; Huang, L. MiR-223 promotes the doxorubicin resistance of colorectal cancer cells via regulating epithelial-mesenchymal transition by targeting FBXW7. *Acta Biochim. Biophys. Sin.* 2018, 50, 597–604. [CrossRef] [PubMed]

127. Wu, X.Z.; Wang, K.P.; Song, H.J.; Xia, J.H.; Jiang, Y.; Wang, Y.L. MiR-27a-3p promotes esophageal cancer cell proliferation via F-box and WD repeat domain-containing 7 (FBXW7) suppression. *Int. J. Clin. Exp. Med.* 2015, 8, 15556–15562. [PubMed]

128. Calcagno, D.Q.; Freitas, V.M.; Leal, M.F.; de Souza, C.R.; Demachki, S.; Montenegro, R.; Assumpcao, P.P.; Khayat, A.S.; Smith Mde, A.; dos Santos, A.K.; et al. MYC, FBXW7 and TP53 copy number variation and expression in gastric cancer. *BMC Gastroenterol.* 2013, 13, 141. [CrossRef] [PubMed]

129. Gong, J.; Cui, Z.; Li, L.; Ma, Q.; Wang, Q.; Gao, Y.; Sun, H. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7. *Tumour Biol.* 2015, 36, 7831–7840. [PubMed]

130. Li, H.; Wang, Z.; Zhang, W.; Qian, K.; Xu, W.; Zhang, S. Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer. *Cancer Lett.* 2016, 370, 39–55. [CrossRef] [PubMed]

131. Jiang, Y.; Qi, X.; Liu, X.; Zhang, J.; Ji, J.; Zhu, Z.; Ren, J.; Yu, Y. Fbxw7 haploinsufficiency loses its protection against DNA damage and accelerates MNU-induced gastric carcinogenesis. *Oncotarget* 2017, 8, 33444–33456. [CrossRef] [PubMed]

132. Li, M.R.; Zhu, C.C.; Ling, T.L.; Zhang, Y.Q.; Xu, J.; Zhao, E.H.; Zhao, G. FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma. *BMC Gastroenterol.* 2017, 17, 60. [CrossRef] [PubMed]

133. O’Neil, J.; Grim, J.; Strack, P.; Rao, S.; Tibbits, D.; Winter, C.; Hardwick, J.; Welcker, M.; Meijerink, J.P.; Pieters, R.; et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. *J. Exp. Med.* 2007, 204, 1813–1824. [CrossRef] [PubMed]

134. Asnafi, V.; Buzyn, A.; Le Noir, S.; Baleydier, F.; Simon, A.; Beldjord, K.; Reman, O.; Witz, F.; Fagot, T.; Tavernier, E.; et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): A Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. *Blood* 2009, 113, 3918–3924. [CrossRef] [PubMed]

135. Inuzuka, H.; Shaik, S.; Onoyama, I.; Gao, D.; Tseng, A.; Maser, R.S.; Zhai, B.; Wan, L.; Gutierrez, A.; Lau, A.W.; et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. *Nature* 2011, 471, 104–109. [CrossRef] [PubMed]

136. Huang, H.L.; Weng, H.Y.; Wang, L.Q.; Yu, C.H.; Huang, Q.J.; Zhao, P.P.; Wen, J.Z.; Zhou, H.; Qu, L.H. Triggering Fbw7-mediated proteasomal degradation of c-Myc by oridonin induces cell growth inhibition and apoptosis. *Mol. Cancer Ther.* 2012, 11, 1155–1165. [CrossRef] [PubMed]

137. Malyukova, A.; Brown, S.; Papa, R.; O’Brien, R.; Giles, J.; Trahair, T.N.; Dalla Pozza, L.; Sutton, R.; Liu, T.; Haber, M.; et al. FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation. *Leukemia* 2013, 27, 1053–1062. [CrossRef] [PubMed]

138. Mansour, M.R.; Sanda, T.; Lawton, L.N.; Li, X.; Kelliher, M.A.; Jamieson, C.H.; et al. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. *Blood* 2009, 113, 3918–3924. [CrossRef] [PubMed]

139. Yeh, C.H.; Bellon, M.; Panczewicz-Wojtkiewicz, J.; Nicot, C. Oncogenic mutations in the FBXW7 gene of adult T-cell leukemia patients. *Proc. Natl. Acad. Sci. USA* 2016, 113, 6731–6736. [CrossRef] [PubMed]

140. Yao, S.; Xu, F.; Chen, Y.; Ge, Y.; Zhang, F.; Huang, H.; Li, L.; Lin, D.; Luo, X.; Xu, J.; et al. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation. *J. Exp. Clin. Cancer Res.* 2017, 36, 10. [CrossRef] [PubMed]

141. Valliyammai, N.; Nancy, N.K.; Sagar, T.G.; Rajkumar, T. Study of NOTCH1 and FBXW7 Mutations and Its Prognostic Significance in South Indian T-Cell Acute Lymphoblastic Leukemia. *J. Pediatr. Hematol. Oncol.* 2018, 40, e1–e8. [CrossRef] [PubMed]
142. Tu, K.; Zheng, X.; Zhou, Z.; Li, C.; Zhang, J.; Gao, J.; Yao, Y.; Liu, Q. Recombinant human adenovirus-p53 injection induced apoptosis in hepatocellular carcinoma cell lines mediated by p53-Fbxw7 pathway, which controls c-Myc and cyclin E. *PLoS ONE* 2013, 8, e68854. [CrossRef] [PubMed]

143. Tu, K.; Yang, W.; Li, C.; Zheng, X.; Lu, Z.; Guo, C.; Yao, Y.; Liu, Q. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. *Mol. Cancer* 2013, 12, 146. [CrossRef] [PubMed]

144. Chen, J.; Wang, H.; Wang, J.; Huang, S.; Zhang, W. STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7. *Cancer Cell Int.* 2015, 15, 111. [CrossRef] [PubMed]

145. Ren, H.; Koo, J.; Guan, B.; Yue, P.; Deng, X.; Chen, M.; Khuri, F.R.; Sun, S.Y. The E3 ubiquitin ligases beta-TrCP and Fbxw7 cooperatively mediate GSK3-dependent Mcl-1 degradation induced by the Akt inhibitor API-1, resulting in apoptosis. *Mol. Cancer* 2013, 12, 146. [CrossRef] [PubMed]

146. Yokobori, T.; Yokoyama, Y.; Mogi, A.; Endoh, H.; Altan, B.; Kosaka, T.; Yamaki, E.; Yajima, T.; Tomizawa, K.; Azuma, Y.; et al. FBXW7 mediates chemotherapeutic sensitivity and prognosis in NSCLCs. *Mol. Cancer Res.* 2014, 12, 32–37. [CrossRef] [PubMed]

147. Liao, S.Y.; Chiang, C.W.; Hsu, C.H.; Chen, Y.T.; Jen, J.; Juan, H.F.; Lai, W.W.; Wang, Y.C. CK1delta/GSK3beta/FBXW7alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression. *Oncogene* 2017, 36, 5722–5733. [CrossRef] [PubMed]

148. Xiao, G.; Zhang, B.; Meng, J.; Wang, J.; Xu, C.; Tang, S.C.; Li, X.; Zhang, J.; Liang, R.; Ren, H.; et al. miR-367 stimulates Wnt cascade activation through degrading FBXW7 in NSCLC stem cells. *Cell Cycle* 2017, 16, 2374–2385. [CrossRef] [PubMed]

149. Ye, M.; Zhang, Y.; Zhang, X.; Jiang, P.; Cao, L.; Li, N.; Li, X.; Yao, L.; Zhang, J.; et al. Targeting FBW7 as a Strategy to Overcome Resistance to Targeted Therapy in Non-Small Cell Lung Cancer. *Cancer Res.* 2017, 77, 3527–3539. [CrossRef] [PubMed]

150. Liu, X.; Ma, J.; Xu, F.; Li, L. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. *Biomed. Pharmacother.* 2018, 99, 9–17. [CrossRef] [PubMed]

151. Xiao, Y.; Yin, C.; Wang, Y.; Lv, H.; Wang, W.; Huang, Y.; Perez-Losada, J.; Snijders, A.M.; Mao, J.H.; Zhang, P. FBXW7 deletion contributes to lung tumor development and confers resistance to gefitinib therapy. *Tumour Biol.* 2017, 39, 2069–2077. [CrossRef] [PubMed]

152. Jiang, J.X.; Sun, C.Y.; Tian, S.; Yu, C.; Chen, M.Y.; Zhang, H. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting beta-catenin for degradation in pancreatic cancer. *Oncol. Rep.* 2015, 33, 1389–1390. [CrossRef] [PubMed]

153. Ishii, N.; Araki, K.; Yokobori, T.; Gantumur, D.; Yamanaka, T.; Altan, B.; Tsukagoshi, M.; Igarashi, T.; Watanabe, A.; Kubo, N.; et al. FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study. *Tumour Biol.* 2016, 37, 13893–13902. [CrossRef] [PubMed]

154. Ji, J.; Hu, C.; Chi, J.; Li, J.; Peng, C.; Yun, X.; Li, D.; Yu, Y.; Li, Y.; Gao, M.; et al. miR-24 promotes the proliferation, migration and invasion in human tongue squamous cell carcinoma by targeting FBXW7. *Oncol. Rep.* 2016, 36, 1143–1149. [CrossRef] [PubMed]

155. Arita, H.; Nagata, M.; Yoshida, R.; Matsuoka, Y.; Hirosue, A.; Kawahara, K.; Sakata, J.; Nakashima, H.; Kojima, T.; Toya, R.; et al. FBXW7 expression affects the response to chemoradiotherapy and overall survival among patients with oral squamous cell carcinoma: A single-center retrospective study. *Tumour Biol.* 2016, 37, 112636–112646. [CrossRef] [PubMed]

156. Hu, Q.; Qin, Y.; Zhang, B.; Liang, C.; Ji, S.; Shi, S.; Xu, W.; Xiang, J.; Liang, D.; Ni, Q.; et al. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of EN1. *Oncol. Rep.* 2017, 38, 2069–2077. [CrossRef] [PubMed]

157. Fu, Y.; Lin, Y.; Yang, Z.; Yang, G.; Li, G.; Liu, Y.; Tan, X.; Huang, Y.; Wu, X.; Wang, Y.; et al. FBXW7 overexpression suppresses renal cancer cell proliferation and induces apoptosis. *Med. Oncol.* 2015, 32, 215. [CrossRef] [PubMed]
159. Cai, Y.; Zhang, M.; Qiu, X.; Wang, B.; Fu, Y.; Zeng, J.; Bai, J.; Yang, G. Upregulation of FBXW7 Suppresses Renal Cancer Metastasis and Epithelial Mesenchymal Transition. *Dis. Markers* 2017, 2017, 8276939. [CrossRef] [PubMed]

160. Ishikawa, Y.; Hosogane, M.; Okuyama, R.; Aoyama, S.; Onoyama, I.; Nakayama, K.I.; Nakayama, K. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch. *Oncogene* 2013, 32, 1921–1932. [CrossRef] [PubMed]

161. Aydin, I.T.; Melamed, R.D.; Adams, S.J.; Castillo-Martin, M.; Demir, A.; Bryk, D.; Brunner, G.; Cordon-Cardo, C.; Osman, I.; Rabadan, R.; et al. FBXW7 mutations in melanoma and a new therapeutic paradigm. *J. Natl. Cancer Inst.* 2014, 106, dju107. [CrossRef] [PubMed]

162. Wei, Z.; Lihua, L.; Qingqing, W. Effects of myeloid specific deficiency of FBXW7 on lung metastasis of murine melanoma. *Zhejiang Da Xue Xue Bao Yi Xue Ban* 2017, 46, 111–117. [PubMed]

163. Abbate, F.; Badal, B.; Mendelson, K.; Aydin, I.T.; Serasinghe, M.N.; Iqbal, R.; Mohammed, J.N.; Solovyov, A.; Greenbaum, B.D.; Chipuk, J.E.; et al. FBXW7 regulates a mitochondrial transcription program by modulating MITF. *Pigment Cell Melanoma Res.* 2018, 31, 636–640. [CrossRef] [PubMed]

164. Wei, G.; Wang, Y.; Zhang, P.; Lu, J.; Mao, J.H. Evaluating the prognostic significance of FBXW7 expression level in human breast cancer by a meta-analysis of transcriptional profiles. *J. Cancer Sci. Ther.* 2012, 4, 299–305. [CrossRef] [PubMed]

165. Strohmaier, H.; Spruck, C.H.; Kaiser, P.; Won, K.A.; Sangfelt, O.; Reed, S.I. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. *Nature* 2001, 413, 316–322. [CrossRef] [PubMed]

166. Ong, P.S.; Wang, L.Z.; Dai, X.; Tseng, S.H.; Sethi, G. Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. *Front. Pharmacol.* 2016, 7, 395. [CrossRef] [PubMed]

167. Baek, S.H.; Ko, J.H.; Lee, J.H.; Kim, C.; Lee, H.; Nam, D.; Lee, J.; Lee, S.G.; Yang, W.M.; Um, J.Y.; et al. Ginkgolic Acid Inhibits Invasion and Migration and TGF-beta-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation. *J. Cell. Physiol.* 2017, 232, 346–354. [CrossRef] [PubMed]

168. Mohan, C.D.; Srinivasa, V.; Rangappa, S.; Mervin, L.; Mohan, S.; Paricharak, S.; Baday, S.; Li, F.; Shanmugam, M.K.; Chinnathambi, A.; et al. Trisubstituted-Imidazoles Induce Apoptosis in Human Breast Cancer Cells by Targeting the Oncogenic PI3K/Akt/mTOR Signaling Pathway. *PLoS ONE* 2016, 11, e0153155. [CrossRef] [PubMed]

169. Ko, J.H.; Nam, D.; Um, J.Y.; Jung, S.H.; Sethi, G.; Ahn, K.S. Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Signaling Cascades and Epithelial-to-Mesenchymal Transition. *Molecules* 2018, 23, 1601. [CrossRef] [PubMed]

170. Lee, H.; Baek, S.H.; Lee, J.H.; Kim, C.; Ko, J.H.; Lee, S.G.; Chinnathambi, A.; Alharbi, S.A.; Yang, W.M.; Um, J.Y.; et al. Isorhynchophylline, a Potent Plant Alkaloid, Induces Apoptotic and Anti-Metastatic Effects in Human Hepatocellular Carcinoma Cells through the Modulation of Diverse Cell Signaling Cascades. *Int. J. Mol. Sci.* 2017, 18, 1095. [CrossRef] [PubMed]

171. Singh, S.S.; Yap, W.N.; Arfuso, F.; Kar, S.; Wang, C.; Cai, W.; Dharmaraj, A.M.; Sethi, G.; Kumar, A.P. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? *World J. Gastroenterol.* 2015, 21, 12261–12273. [CrossRef] [PubMed]

172. Siveen, K.S.; Ahn, K.S.; Ong, T.H.; Shanmugam, M.K.; Li, F.; Yap, W.N.; Kumar, A.P.; Fong, C.W.; Tergaonkar, V.; Hu, K.M.; et al. Y-tocotrienol inhibits angiogenesis-dependent growth of human hepatocellular carcinoma through abrogation of AKT/mTOR pathway in an orthotopic mouse model. *Oncotarget* 2014, 5, 1897–1911. [CrossRef] [PubMed]

173. Kannaiyan, R.; Manu, K.A.; Chen, L.; Li, F.; Rajendran, P.; Subramaniam, A.; Lam, P.; Kumar, A.P.; Sethi, G. Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. *Apoptosis* 2011, 16, 1028–1041. [CrossRef] [PubMed]
175. Sethi, G.; Ahn, K.S.; Sung, B.; Kunnumakkara, A.B.; Chaturvedi, M.M.; Aggarwal, B.B. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBeta kinase activation. *Biochem. Pharmacol.* 2008, 76, 1404–1416. [CrossRef] [PubMed]

176. Kogita, A.; Yoshioka, Y.; Sakai, K.; Togashi, Y.; Sogabe, S.; Nakai, T.; Okuno, K.; Nishio, K. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis. *Biochem. Biophys. Res. Commun.* 2015, 458, 52–56. [CrossRef] [PubMed]

177. Korphasarn, K.; Morris, V.K.; Overman, M.J.; Fogelman, D.R.; Kee, B.K.; Raghav, K.P.S.; Manuel, S.; Shureiqi, I.; Wolff, R.A.; Eng, C.; et al. FBXW7 missense mutation: A novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget* 2017, 8, 39268–39279. [CrossRef] [PubMed]

178. Naganawa, Y.; Ishiguro, H.; Kuwabara, Y.; Kimura, M.; Mitsui, A.; Katada, T.; Tanaka, T.; Shiozaki, M.; Yokobori, T.; Mimori, K.; Iwatsuki, M.; Ishii, H.; Tanaka, F.; Sato, T.; Toh, H.; Sudo, T.; Iwaya, T.; Tanaka, Y.; Gong, L.; Ren, M.; Lv, Z.; Yang, Y.; Wang, Z. miR-92b-3p Promotes Colorectal Carcinoma Cell Proliferation, Invasion, and Migration by Inhibiting FBXW7 In vitro and In vivo. *DNA Cell Biol.* 2018, 37, 501–511. [CrossRef] [PubMed]

179. Li, N.; Lorenzi, F.; Kalakouti, E.; Normatova, M.; Babaei-Jadidi, R.; Tomlinson, I.; Nateri, A.S. FBXW7-mutated T-cell acute lymphocytic leukemias. *Leuk. Res.* 2008, 32, 1825–1835. [CrossRef] [PubMed]

180. Korphaisarn, K.; Morris, V.K.; Overman, M.J.; Fogelman, D.R.; Kee, B.K.; Raghav, K.P.S.; Manuel, S.; Shureiqi, I.; Wolff, R.A.; Eng, C.; et al. FBXW7 missense mutation: A novel negative prognostic factor in metastatic colorectal adenocarcinoma. *Oncotarget* 2017, 8, 39268–39279. [CrossRef] [PubMed]

181. Yokobori, T.; Watanabe, M.; Iwatsuki, M.; Kinoshita, K.; Saito, S.; Hiyoshi, Y.; Kamohara, H.; Baba, Y.; Mimori, K.; Baba, H. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. *Br. J. Cancer* 2012, 106, 182–188. [CrossRef] [PubMed]

182. Eto, K.; Iwatsuki, M.; Watanabe, M.; Ishimoto, T.; Ida, S.; Inamura, Y.; Iwagami, S.; Baba, Y.; Sakamoto, Y.; Miyamoto, Y.; et al. The sensitivity of gastric cancer to trastuzumab is regulated by the miR-223/FBXW7 pathway. *Br. J. Cancer* 2015, 136, 1537–1545. [CrossRef] [PubMed]

183. Lee, J.W.; Soung, Y.H.; Kim, H.J.; Park, W.S.; Nam, S.W.; Kim, S.H.; Lee, J.Y.; Yoo, N.J.; Lee, S.H. Mutational analysis of the hCDC4 gene in gastric carcinomas. *Eur. J. Cancer* 2006, 42, 2369–2373. [CrossRef] [PubMed]

184. Milhe, A.N.; Leguit, R.; Corver, W.E.; Morsink, F.H.; Polak, M.; de Leng, W.W.; Carvalho, R.; Offerhaus, G.J. Loss of CDC4/FBXW7 in gastric carcinoma. *Cell Oncol.* 2010, 32, 347–359. [CrossRef] [PubMed]

185. Kurashige, J.; Watanabe, M.; Iwatsuki, M.; Kinoshita, K.; Saito, S.; Hiyoshi, Y.; Kamohara, H.; Baba, Y.; Mimori, K.; Baba, H. Overexpression of microRNA-223 regulates the ubiquitin ligase FBXW7 in oesophageal squamous cell carcinoma. *Br. J. Cancer* 2012, 106, 182–188. [CrossRef] [PubMed]

186. Sun, D.; Shen, Y.; Wang, S.H.; Xiang, Z.W.; Xie, Y.S.; Jiang, X. Effects of UO-126 on proliferation and fbw7 expression of HeLa cells. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 2013, 38, 1383–1390. [PubMed]

187. Zhou, Z.Y.; Tu, K.S.; Zhang, J.; Zheng, X.; Gao, J.; Yao, Y.M.; Liu, Q.G. Expression of Fbxw7 and its correlation with cell proliferation in human hepatocellular carcinoma. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi* 2012, 28, 1303–1306. [PubMed]

188. Song, J.H.; Schnittke, N.; Zaat, A.; Walsh, C.S.; Miller, C.W. FBXW7 mutation in adult T-cell and B-cell acute lymphocytic leukemias. *Leuk. Res.* 2008, 32, 1751–1755. [CrossRef] [PubMed]

189. Kraszewska, M.D.; Dawidowska, M.; Kosmalska, M.; Sadek, L.; Grzeszczak, W.; Kowalczyk, J.R.; Szczepanski, T.; Witt, M. BCL11B, FLT3, NOTCH1 and FBXW7 mutation status in T-cell acute lymphoblastic leukemia patients. *Blood Cells Mol. Dis.* 2013, 50, 33–38. [CrossRef] [PubMed]

190. Thompson, B.J.; Buonomici, S.; Sulis, M.L.; Palomero, T.; Vilimas, T.; Basso, G.; Ferrando, A.; Aifantis, I. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. *J. Exp. Med.* 2007, 204, 1825–1835. [CrossRef] [PubMed]

191. Baldus, C.D.; Thibaut, J.; Goebbuget, N.; Stroux, A.; Schlee, C.; Mossner, M.; Burmeister, T.; Schwartz, S.; Bloomfield, C.D.; Hoelzer, D.; et al. Prognostic implications of NOTCH1 and FBXW7 mutations in adult acute T-lymphoblastic leukemia. *Haematologica* 2009, 94, 1383–1390. [CrossRef] [PubMed]
193. Mihashi, Y.; Mizoguchi, M.; Takamatsu, Y.; Ishitsuka, K.; Iwasaki, H.; Koga, M.; Urabe, K.; Mamosaki, S.; Sakata, T.; Kiyomi, F.; et al. C-MYC and Its Main Ubiquitin Ligase, FBXW7, Influence Cell Proliferation and Prognosis in Adult T-cell Leukemia/Lymphoma. *Am. J. Surg. Pathol.* 2017, 41, 1139–1149. [CrossRef] [PubMed]

194. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.; Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* 2013, 6, pl1. [CrossRef] [PubMed]

195. Villaruz, L.C.; Socinski, M.A. Temsirolimus therapy in a patient with lung adenocarcinoma harboring an FBXW7 mutation. *Lung Cancer* 2014, 83, 300–301. [CrossRef] [PubMed]

196. Calhoun, E.S.; Jones, J.B.; Ashfaq, R.; Adsay, V.; Baker, S.J.; Valentine, V.; Hempen, P.M.; Hilgers, W.; Yeo, C.J.; Hruban, R.H.; et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: Potential therapeutic targets. *Am. J. Pathol.* 2003, 163, 1255–1260. [CrossRef]

197. Koh, M.S.; Ittmann, M.; Kadmon, D.; Thompson, T.C.; Leach, F.S. CDC4 gene expression as potential biomarker for targeted therapy in prostate cancer. *Cancer Biol. Ther.* 2006, 5, 78–83. [CrossRef] [PubMed]

198. Li, Z.; Sun, Y.; Chen, X.; Squires, J.; Nowroozizadeh, B.; Jiang, C.; Huang, J. p53 Mutation Directs AURKA Overexpression via miR-25 and FBXW7 in Prostatic Small Cell Neuroendocrine Carcinoma. *Mol. Cancer Res.* 2015, 13, 584–591. [CrossRef] [PubMed]

199. Williams, R.D.; Al-Saadi, R.; Chagtai, T.; Popov, S.; Messahel, B.; Sebire, N.; Gessler, M.; Wegert, J.; Graf, N.; Leuschner, I.; et al. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms’ tumor. *Clin. Cancer Res.* 2010, 16, 2036–2045. [CrossRef] [PubMed]

200. Enkhbold, C.; Utsunomiya, T.; Morine, Y.; Imura, S.; Ikemoto, T.; Arakawa, Y.; Kanamoto, M.; Iwahashi, S.; Saito, Y.; Ishikawa, D.; et al. Loss of FBXW7 expression is associated with poor prognosis in intrahepatic cholangiocarcinoma. *Hepatol. Res.* 2014, 44, E346–E352. [CrossRef] [PubMed]

201. Xu, Y.; Yu, J.; Liu, T.; Meng, F.; Kong, D.; Lou, G. Loss of FBXW7 is related to the susceptibility and poor prognosis of cervical squamous carcinoma. *Biomarkers* 2016, 21, 379–385. [CrossRef] [PubMed]

202. Takeishi, S.; Matsumoto, A.; Onoyma, I.; Na, K.; Hirao, A.; Nakayama, K.I. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. *Cancer Cell* 2013, 23, 347–361. [CrossRef] [PubMed]

203. Izumi, D.; Ishimoto, T.; Miyake, K.; Eto, T.; Arima, K.; Kiyozumi, Y.; Uchihara, T.; Kurashige, J.; Iwatsuki, M.; Baba, Y.; et al. Colorectal Cancer Stem Cells Acquire Chemoresistance Through the Upregulation of F-Box/WD Repeat-Containing Protein 7 and the Consequent Degradation of c-Myc. *Stem Cells* 2017, 35, 2027–2036. [CrossRef] [PubMed]

204. Yu, J.; Zhang, W.; Gao, F.; Liu, Y.Y.; Chen, Z.Y.; Cheng, L.Y.; Xie, S.F.; Zheng, S.S. FBW7 increases chemosensitivity in hepatocellular carcinoma cells through suppression of epithelial-mesenchymal transition. *Hepatobiliary Pancreat. Dis. Int.* 2014, 13, 184–191. [CrossRef]

205. Yu, H.G.; Wei, W.; Xia, L.H.; Han, W.L.; Zhao, P.; Wu, S.J.; Li, W.D.; Chen, W. FBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cells. *Asian Pac. J. Cancer Prev.* 2013, 14, 6321–6326. [CrossRef] [PubMed]

206. Song, Y.; Zhou, X.; Bai, W.; Ma, X. FBW7 increases drug sensitivity to cisplatin in human nasopharyngeal carcinoma by downregulating the expression of multidrug resistance-associated protein. *Tumour Biol.* 2015, 36, 4197–4202. [CrossRef] [PubMed]

207. Yeh, C.H.; Bellon, M.; Nicot, C. FBXW7: A critical tumor suppressor of human cancers. *Mol. Cancer* 2018, 17, 115. [CrossRef] [PubMed]